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ABSTRACT 
 
Background: Cardiac rehabilitation (CR) reach is minimal globally, primarily due to financial 
factors. This study characterized CR funding sources, cost to patients to participate, cost to 
programs to serve patients, and the drivers of these costs. 
Methods: In this cross-sectional study, an online survey was administered to CR programs 
globally. Cardiac associations and local champions facilitated program identification. Costs in 
each country were reported using purchasing power parity (PPP). Results were compared by 
World Bank country income classification using generalized linear mixed models.  
Results: 111/203 (54.68%) countries in the world offer CR, of which data were collected in 93 
(83.78% country response rate; N=1082 surveys, 32.0% program response rate). CR was most-
often publicly funded (more in high-income countries [HICs]; p<.001), but in 60.20% of 
countries patients paid some or all of the cost. Funding source impacted capacity (p=.004), 
number of patients per exercise session (p<.001), personnel (p=.037), and functional capacity 
testing (p=.039). The median cost to serve 1 patient was $945.91PPP globally. In low and 
middle-income countries (LMICs), exercise equipment and stress testing were perceived as the 
most expensive delivery elements, with front-line personnel costs perceived as costlier in HICs 
(p=.003). Modifiable factors associated with higher costs included CR team composition 
(p=.001), stress testing (p=.002) and telemetry monitoring in HICs (p=.01), and not offering 
alternative models in LMICs (p=.02).  
Conclusions: Too many patients are paying out-of-pocket for CR, and more public funding is 
needed. Lower-cost delivery approaches are imperative, and include walk tests, task-shifting, and 
intensity monitoring via perceived exertion.   
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INTRODUCTION 
 
Cardiovascular disease (CVD) is among the leading burdens of disease and disability 
globally.1 Due to advances in acute treatment, there are many patients living chronically with 
CVD. They are at risk for recurrent events and require long-term follow-up and management. 
This includes regular visits with specialists, testing of their cardiovascular risk factors and 
function, taking on average 3-4 classes of medications, and participating in cardiac rehabilitation 
(CR).    
 The costs of CVD to the healthcare system have previously been characterized,2–4  and 
are substantial. CVD is the costliest of any health condition. However, there has been little 
consideration of the costs (not only out-of-pocket [OOP] costs, but also time-related costs) to 
patients to attend visits for tests and treatments, as well as for medications.5 These have been 
characterized in cancer patients, who also require ongoing monitoring and management. 6 In a 
publicly-funded healthcare system or one with a good system of private healthcare insurance, 
costs to patients would certainly be lower than in systems without such coverage. In Canada for 
example, healthcare services are generally covered, but there is limited coverage of medications 
for those <65 years old. These patients must pay OOP, if they do not have a benefit plan through 
an employer or purchased privately.  
Moreover, patients may miss paid work due to disability or need to pay OOP for 
household assistance. They may need to go on long-term disability or retire. This also has 
important financial ramifications for patients. 
CR is a chronic disease management program that successfully prolongs quality and 
quantity of life,7 and hence clinical practice guidelines recommend CVD patients participate.8,9 
Most patients attend supervised programs located in academic hospitals;10 on average patients 
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attend 2-3 times per week for 5 months.11 There is wide variation around the world however in 
terms of whether these services are reimbursed (by government or private insurers), or whether 
patients must pay OOP. Moreover, efforts to promote sustained exercise in CR grads are 
necessary, but little is known about the costs to deliver these services. Indeed, the costs to 
programs and to patients to participate in CR and transition to self-management have been 
scantly characterized12–14.   
Through this dissertation, patient costs for cardiac care will be characterized, including 
consideration of loss of productivity, and participation in CR. The costs to deliver CR (including 
post-program maintenance interventions), how it is reimbursed, and the degree to which financial 
resources are barriers to delivery will be characterized around the globe. 
REVIEW OF LITERATURE 
 
CVD is a class of diseases that involve the heart or blood vessels. It is recognized as the 
leading cause of death worldwide15 and among the leading causes of death and disability in 
Canada16. In 2013, 32% of global deaths were attributable to CVD15. In Canada, CVD makes up 
25% of the national burden of disease17. One in every 20 Canadians reports being diagnosed with 
a CVD, but the actual number with undetected heart disease is much higher18.  
In addition to health impacts, CVD also poses a major economic burden on patients, their 
families and society. This is due to productivity loss and costs of care19. Evidence suggests that 
CVD pushes approximately 10% of affected families into poverty in low and middle-income 
countries where there is limited public healthcare20. Furthermore, due to disability caused by 
CVD, individuals may require assistance with activities of daily living, which are costly, as well 
as financial support if they cannot work19.  
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In Canada, CVD is the largest health-related economic cost, with major direct (i.e. 
hospital care, drugs, physician care, other institutional care) and indirect (i.e. mortality, and short 
and long-term disability) costs. This cost has increased over recent years and now amounts to 
CAD$22 billion per year, with 3 of the top 4 most expensive health conditions in Canada being 
CVDs.18,21 On a global level, it is predicted that by 2030, the total cost of CVD will rise to a 
staggering US$1,044 billion (from US $863 billion in 2010)22. 
Secondary Prevention of Cardiovascular Disease 
While CVD mortality has been declining in Canada due to advances in acute treatment, 
there are many Canadians living chronically with CVDs. These patients are at high risk of 
recurrent events. As a result, secondary prevention is crucial. This includes follow-up with 
cardiac specialists, regular testing to monitor disease status, and on-going treatment. Diagnostic 
tests include X-rays, electrocardiograms, blood and urine tests, CT scans, echocardiograms and 
stress tests. Treatment consists of approximately 5 medications and may include repeat 
revascularization, among other therapies.  
The time and OOP costs for cardiac patients to attend these visits, have these tests and 
undergo recommended treatments are not well characterized, particularly in high-income 
countries (HICs) such as Canada and those with public healthcare. While one would assume 
costs under public healthcare would not be prohibitive, this should be understood, particularly 
because there are socioeconomic disparities. In India, OOP expenditures for CVD treatment have 
been shown to have a major economic burden on patient households23,24.  
A study in Ontario cancer patients suggests that time and OOP costs for survivor care can 
represent a substantial burden, particularly for lower-income patients6 where total costs represent 
10% of income for these patients. Some patients had higher costs than others, namely those with 
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radical prostatectomy, younger age, poor urinary function, current androgen deprivation therapy 
and recent cancer diagnosis, however, only urinary function significantly affected total cost.   
Cardiac Rehabilitation 
 
CR is a comprehensive chronic disease management program model designed to reduce 
risk in patients with established CVD. Due to its’ established benefits7, CR is recommended for 
outpatients with CVDs. 25–27 CR services are provided through an interdisciplinary approach to 
promote cardiovascular risk reduction, and heart-healthy behaviour. The core components of CR 
include: risk factor assessment, patient education, lifestyle risk factor management (physical 
activity and weight management, diet and smoking cessation), psychosocial health, and medical 
risk factor management.28–30 
Unfortunately, CR is grossly under-used31. While there are factors at the patient-level32, 
much of the reason for this relates to lack of financial resources, be it for personnel or space for 
example. Indeed, surveys of CR programs in Australia and New Zealand33, China34, Japan35, 
Scotland36, Spain37, Latin America and the Carribbean38, South America39, Mexico40 Arab 
Region and Canada41 report financial issues as a primary barrier to broader delivery of services.   
Cardiac Rehabilitation Cost  
 
Little is known about the costs to deliver CR around the world. Recently, the 
International Council of Cardiovascular Prevention and Rehabilitation (ICCPR) surveyed 
countries around the globe regarding CR delivery costs as well as reimbursement sources and 
policies. When asked who reimburses CR in their country (respondents were asked to check all 
that apply), 61% reported the government, 55% reported patients pay OOP, and 52% reported 
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insurance companies19. These findings suggest that many patients pay OOP for CR services and 
thus a better understanding of these costs is needed, given the likely impacts on utilization rates. 
Traditional CR consists primarily of supervised exercise sessions delivered in an 
outpatient setting, such as a hospital or clinic. Overall, delivering the traditional model of CR 
carries with it costs associated with personnel, equipment and other supplies, space and other 
operating costs12,13,42. Only a handful of studies have reported all costs to run a program per 
patient. For example, the study by Oldridge et al. in Canada reported direct costs for a 16-session 
supervised program were: space $290CAD (1987; Purchasing Power Parity PPP$506 in 2016 
dollars), overall personnel $148 (PPP$258), equipment $64 (PPP$112), and resource literature 
$5 (PPP$9), for a total of $PPP88413.The study by Whittaker et al. reported the costs of 6-week 
supervised program were overall $1845AUD (2013; PPP$1,312), comprised of facility $595 
(PPP$423), administration $450 (PPP$320), coaching and mentoring $225 (PPP$160), 
assessment $195 (PPP$139), gymnasium $180 (PPP$128), communications $125 (PPP$89), 
technology $40 (PPP$28) and education $35 (PPP$25) costs12. Clearly, delivery costs will vary 
greatly based on the density of patients served per session, whether patients are monitored during 
exercise using telemetry or other less-expensive means, the type of equipment used, and 
personnel composition.   
The cost to run alternative models of CR have also been described12,43. As reported by 
Whittaker et al. a 6-week telehealth-enabled home-based CR program costs $1633AUD (2013; 
PPP$1112)12. A systematic review by Taylor et al. found home-based CR to be equally effective 
as centre-based CR in improving clinical and health-related quality of life outcomes, while 
having similar costs43. Carlson et al. demonstrated that a modified CR program with reduced 
ECG monitoring is less costly (PPP$2060 vs. PPP$3187) and as effective in improving 
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physiological outcomes in patients44. A study by Kraal et al. showed home-based CR was 
PPP$3400 less expensive compared to hospital-based CR and had higher patient satisfaction45.  
Low-cost models of CR can include telehealth, home-based and community-based 
programs, and can have comparable or better efficacy to traditional programs. Telehealth has 
been shown to be less costly and produce similar clinical outcomes in patients compared to 
supervised CR12,46,47. Moreover, it improves access to care and CR completion rates. The 
Fit@home study showed a home-based model was more cost-effective compared to supervised 
CR, while producing similar results in physical fitness and health-related quality of life45. In 
addition, a community-based model of CR had similar effects on medication and risk factors 
compared to a supervised, hospital-based program, although costs were not examined48. Southard 
et al. showed a 6-month internet-facilitated home-based CR program was less costly compared to 
usual care in patients with CVD49. Moreover, a heart disease self-management program (similar 
to CR) in women with cardiac disease resulted in lower costs and reduced health care utilization 
compared to usual care50.  
The available literature on CR personnel costs specifically is displayed in Table 1. Given 
the multi-component nature of CR, and hence the multiple disciplines required to deliver it 
comprehensively, personnel costs are quite high. There is wide variation in the staffing 
complement of CR programs as well as staff-to-patient ratios during exercise for safety41,51,52, 
and hence correspondingly overall costs to programs would vary. The value of the personnel 
with respect to achieving beneficial patient outcomes is not reflected, but strategies to mitigate 
these costs are considered below.  
The available literature on the cost of delivering each of the core CR components is 
displayed in Table 2. For some medications and smoking cessation, data was available for cost of 
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secondary prevention but outside of CR settings. Very little is known about costs to promote 
maintenance of physical activity post-program. 
The overall cost of delivering supervised CR was expressed on a per patient (for a 
complete program), or per session basis in the literature. Table 3 summarizes the available data 
on the cost to deliver traditional CR by country, sorted by country income classification. As can 
be shown, these costs are considerably less expensive than the cost of acute cardiac procedures31. 
In HICs, the cost to deliver a supervised CR session ranged from PPP$12 in Finland to PPP$310 
in Italy.  
Available data on CR delivery costs in low- and middle-income countries (LMICs) is 
also shown in Table 3. As shown, there is only information on delivery in MICs in South 
America. Interestingly, delivery costs are higher in private versus public healthcare, except in 
Paraguay. Unfortunately, whether these costs can be attributed to differences in CR care quality 
in these settings is not known, but the lower cost is likely due to higher volume (personal 
communication, Claudia Anchique Santos, December 18, 2016). The review by Oldridge et al. 
juxtaposed these overall CR costs in relation to healthcare expenditure per capita53. It was 
concluded that CR as delivered traditionally was not affordable in the LIC setting, but was in 
MICs.  
Finally, one must consider costs to patients to attend CR. Patients attending supervised 
programs have to incur expenses related to transportation (including parking), as well as time 
costs. These have been characterized in a few studies12,13,54, and can be considerable. These 
likely also vary widely by country / region given, the broad variation in CR session frequency 
and program duration51,55. Lost productivity to attend supervised sessions must also be 
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considered. Recent research has shown that delivery of unsupervised CR costs considerably less 
for patients12; equivalent benefits are achieved in these settings46,47,56.  
DISSERTATION OBJECTIVES 
 
Study #1-CVD Outpatient Costs, Including CR.  
The objectives of this study were to: (1) describe cardiac healthcare utilization (including 
CR) and associated patient time and out-of-pocket costs (OOP) over 2 years following a CVD 
diagnosis or event; (2) understand the drivers of time and OOP costs incurred by outpatients 
living with CVD, namely sociodemographic (e.g., age, sex, work status, educational level, 
marital status, ethnocultural background, area of residence), and clinical (e.g., smoking, disease 
severity, and functional capacity); and (3) describe patient’s time and OOP costs related to CR 
participation.   
Study #2 -Global Comparison of Costs to Deliver CR.  
The objectives of this study were to characterize: (1) funding source, and (1b) the 
proportion of the program cost as well as (1c) direct cost, to patients where they pay for CR; and 
(2) the estimated cost to CR programs to provide service to 1 patient, (2b) which elements of the 
program were perceived as most expensive, and (2c) whether cost varies by funding source. The 
association of: (3i) a program’s patient capacity per year, (ii) the number and nature of healthcare 
professionals on the CR team, (iii) the number of patients served per exercise session (including 
staff-to-patient ratio), (iv) the number and nature of core components the program delivers; (v) 
the dose of CR (i.e., sessions per week x duration in weeks x duration of exercise sessions in 
minutes); (vi) the equipment/resources the program has (e.g., exercise equipment, supplies for 
cardiovascular risk assessment) including whether patients are monitored during exercise using 
telemetry, and (vii) whether the program offers alternative CR models (i.e., home or community-
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based) to both funding source and cost to treat 1 patient were explored to understand factors that 
impact CR delivery costs. Finally, (4) the degree to which financial and other resources serve as 
barriers to CR delivery were described. Each were compared by country income classification 
(i.e., high vs LMICs; http://data.worldbank.org/country), and described in all countries of the 
world where CR is offered.   
Study #3- Costs to Promote Exercise Maintenance in CR Graduates 
The objective of the last study was to determine the costs to promote exercise 
maintenance post-CR in a randomized controlled trial of CR graduates. In particular, the 
objective was to assess costs for implementing an exercise facilitator intervention for 52 weeks.  
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Healthcare Utilization and Associated Time and Out-of-Pocket Expenditures for Cardiovascular 
Disease Patients in a Publicly-Funded Healthcare System 
 
Abstract 
 
Background: The objectives of this study were to describe: (1) healthcare utilization and 
associated patient time and out-of-pocket costs (OOP) over 2 years following a cardiac 
diagnosis, (2) the sociodemographic and clinical drivers of these costs, and (3) patient costs 
related to cardiac rehabilitation (CR) participation.   
Methods: Secondary analysis was conducted on an observational, prospective CR program 
evaluation cohort in Ontario which has a publicly-funded healthcare system. A convenience 
sample of patients from one of 3 CR programs was approached at their first visit, and consenting 
participants completed a survey. Participants were emailed surveys again 6 months, 1 and 2 years 
later; these assessed their cardiac care and medications, and the time and OOP costs associated 
with care visits. Patient time was valued based on average wages in Ontario. 
Results: Of 411 consenting patients, 240 (58.3%) completed CR, and 192 (46.7%) were retained 
at 2 years. Patients most often had visits to their general practitioner, electrocardiograms, and 
treatment for angina. The total cost to patients over 2 years was $73.70±275.84 for time and 
$377.01±321.72 for OOP costs ($525.93±467.08 overall). With adjustment, there was a trend 
towards higher OOP costs for females (p=.09), and less educated (p=.07) patients. Participants 
spent considerable money relatively OOP on CR visits alone ($384.78±269.67), with time costs 
at $379.07±1035.49 ($939.43±1333.29 overall; 1.6% share of 1 year’s income).  
Conclusions: In conclusion, time and OOP costs are modest for cardiac patients, except for CR. 
Alternative delivery models are needed, in particular for low-income patients.   
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INTRODUCTION 
Cardiovascular disease (CVD) is among the leading burdens of disease and disability 
globally.1 Due to advances in acute treatment, there are many patients living chronically with 
CVD. They are at risk for recurrent events, and require long-term follow-up and management. 
This includes regular visits with specialists, testing of their cardiovascular risk factors and 
function, taking on average 3-4 classes of medications, and participating in cardiac rehabilitation 
(CR).    
 The costs of CVD to the healthcare system have previously been characterized,2,3,4 and 
are substantial. CVD is the costliest of any health condition. However, there has been little 
consideration of the costs (not only out-of-pocket [OOP] costs, but also time-related costs) to 
patients to attend visits for tests and treatments, including CR, as well as for medications.5 These 
have been characterized in cancer patients, who also require ongoing monitoring and 
management.6 In a publicly-funded healthcare system or one with a good system of private 
healthcare insurance, costs to patients would certainly be lower than in systems without such 
coverage. In Canada for example, healthcare services are generally covered, but there is limited 
coverage of medications for those <65 years old (except in Quebec which has a publicly-funded 
medication coverage plan, or the Ontario Trillium Drug Program for those who are eligible when 
costs are > 4% of income, for example). These patients must pay OOP if they do not have a 
benefit plan through an employer or purchased privately.  
 CR is a chronic disease management program that successfully prolongs quality and 
quantity of life,7 and clinical practice guidelines recommend CVD patients participate.8,9 Most 
patients attend supervised programs located in academic centers;10 on average patients attend 2-3 
times per week for 5 months.11 While CR services are reimbursed in some jurisdictions in 
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Canada, there can also be significant costs borne by patients associated with transportation and 
parking at hospitals. These have been infrequently considered12 (and only characterized once in 
Canada approximately 25 years ago);13 costs for CR sessions when not reimbursed by 
government or private insurance companies are also scantly reported.5 In addition, most 
programs offer sessions during business hours,14 and therefore participants must miss paid work 
to attend.     
 The objectives of this study were to: (1a) describe healthcare utilization and associated 
patient time and out-of-pocket costs (OOP) over 2 years following a CVD diagnosis or event; (2) 
understand the drivers of time and OOP costs incurred by outpatients living with CVD, namely 
sociodemographic (e.g., age, sex, work status, educational level, marital status, ethnocultural 
background, area of residence), and clinical (e.g., smoking, disease severity, and functional 
capacity); and (3) describe patient’s time and OOP costs related to CR participation.   
METHODS 
Design and Procedure 
We conducted this prospective, observational study as part of a CR program evaluation. 
Approval was received from the research ethics review boards at the institutions of each 
participating CR site.  Patients referred to CR at one of 4 centers following a qualifying 
hospitalization or diagnosis were approached to participate at their initial visit between July 2010 
and February 2014. Based on median times from hospital discharge to CR initiation in the 
region,15 baseline assessment would have occurred approximately 1.5 months post 
event/procedure.  Consenting participants were asked to complete surveys at CR intake and 
discharge (or the expected time of graduation for those who did not complete), as well as 1 and 2 
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years from CR initiation (online or paper). Clinical data were extracted from participants’ 
medical charts for their CR intake and discharge assessments (where available).  
Setting and Participants  
This study was undertaken in Canada, which has a publicly-funded healthcare system. 
Therefore, all CVD tests and acute treatments are covered by provincial health insurance plans. 
There is a pharmacare program for Canadians above the age of 65. Most patients under the age 
of 65 years must pay OOP for medications, unless they have a very low income or very high 
medication costs in proportion to their annual income, have a health benefit plan through an 
employer or purchase a benefit plan privately.  
The cohort consisted of participants from 3 CR sites and one satellite program in the 
Greater Toronto Area of Ontario, Canada. The attributes of each site are described elsewhere.16 
In brief, one program was located within the city and the others in the suburbs of Toronto.  The 
programs were 4-6 months in duration, offering 1-2 sessions / week. Three programs offered CR 
at no cost to participants (one program charged a nominal fee for educational materials). In the 
remaining program, patients were required to pay a monthly fee of $55CDN to participate, which 
was reimbursable through private healthcare insurance for patients with such coverage (i.e., 
through work or purchased privately). This fee was added to OOP costs for participants attending 
this program (i.e., $55 x 6 months).   
This convenience sample consisted of all consenting participants attending an initial visit 
at 1 of the CR programs. Participants were generally systematically referred to the CR programs 
following hospitalization for cardiac conditions or procedures, such as: acute coronary 
syndrome, chronic stable angina, or stable heart failure, as well as percutaneous coronary or 
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valvular intervention, coronary artery bypass graft (CABG) ± valve surgery, cardiac 
transplantation, or mild non-disabling stroke.17 The inclusion criterion was that participants were 
deemed eligible to complete CR following the intake assessment (i.e. no co-morbidities 
identified or indications from the exercise stress test that would preclude CR participation). 
Participants who were not proficient in the English language were excluded from the study.   
Measures 
 Sociodemographic characteristics such as participants’ ethnocultural background 
(adapted from Statistics Canada categorizations), marital status, highest educational attainment 
and work status (also assessed in the 2nd survey), were assessed via self-report in the initial 
survey. Participants from the CR program in the city were considered “urban” for their area of 
residence, with those attending the other programs considered “suburban”.  Age, sex, as well as 
clinical data were extracted from CR referral forms, as well as CR intake and discharge 
assessments, where available. The following variables were collected: CR referral indications, 
and cardiac risk factors (e.g., blood pressure, lipids, blood glucose, and anthropometrics; 
smoking was assessed via self-report). Functional capacity was obtained from the graded 
exercise stress test at intake (i.e., peak Metabolic Equivalents of Task [METs]), and the Duke 
Activity Status Index18 was administered in the discharge survey.  
Patient Costs Related to Cardiac Healthcare Utilization  
CVD-related healthcare utilization was assessed via self-report at each assessment point 
following intake. Participants were asked to report the number of times they visited a primary 
and specialist care provider, as well as emergency department visits and hospital admissions. 
They were also asked to indicate whether they had experienced any in a list of CVD-related tests, 
events or procedures. Completion of CR was ascertained from CR charts where available 
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(defined as engagement to a sufficient degree in the program to warrant formal post-program re-
assessment and completion of said re-assessment);19 otherwise dropout of CR was confirmed via 
self-report in the discharge survey. Healthcare system costs were not considered. 
Patient OOP and time costs were assessed via self-report in each follow-up survey. Items 
were based on those developed for cancer survivors,6 and adapted for cardiac patients. 
Participants were asked to report OOP costs (e.g., transportation, parking, food) as well as time 
(e.g., “in the last 12 months, how much time was associated with these health care visits, 
including travel and waiting?”) for the above healthcare visits, tests and treatments, including 
costs for any accompanying persons. Whether participants lost time from paid work, and 
required assistance with unpaid work were also assessed in the CR discharge survey specifically. 
Participants were asked to report costs since the last assessment point (i.e., the discharge / 6-
month survey assessed costs since CR intake; the 1 year survey assessed costs since the 6 month 
survey and the 2 year survey assessed costs for the full year). 
Patient cost for medication was assessed in the 1 year and 2-year follow-up surveys. 
Participants were asked to list all of their cardiac-related prescribed and herbal/alternative 
medications, whether secured over (e.g., acetylsalicylic acid) or under-the-counter. Participants 
were asked to list them from the pill bottles to ensure accurate responses. They were then asked 
to self-report OOP costs for these medications during the previous 12 months. Finally, OOP 
costs associated with CR (e.g., transportation to and from each session, parking, shoes) and time 
associated with CR participation (i.e., travel to and from sessions) were assessed in the discharge 
survey only, based on Oldridge et al.13   
Patient time was valued as per the average hourly wages in August 2016 in Ontario, 
namely $28.76/hour for those above the age of 55 (http://www.statcan.gc.ca/tables-
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tableaux/sum-som/l01/cst01/labr69g-eng.htm; based on 50 weeks of work / year @ 40 hours / 
week this would be $57,520/year [value also used to calculate share of income]). This was 
computed relative to work status: the hourly wage was multiplied by the patient time among 
those working full-time, multiplied by half the hourly wage among those working part-time, and 
no time cost was computed for those reporting any other work status (e.g., retired, on disability). 
Total patient time cost was calculated for each follow-up time point, and summed for a grand 
total time cost across the 2 years from CR initiation. Total OOP costs, namely costs for 
healthcare visits and medications, were similarly summed at each assessment point, and then 
across all assessment points for a grand total. This was only computed in participants who 
completed surveys at all 3 assessment points. Finally, OOP and time costs were also averaged, to 
ascertain total patient cost. Unit cost for medical tests and procedures were obtained from the 
Patient Cost Estimator tool developed by the Canadian Institute for Health Information 
https://www.cihi.ca/en/patient-cost-estimator and the Schedule of Benefits, Ministry of Health 
and Long Term Care. Total costs were calculated by multiplying the unit costs by the frequency 
of visits across all time points. 
Statistical Analysis  
IBM SPSS software version 24 (IBM, Armonk, NY) was used for statistical analysis.  A 
significance cut-off value of p < .05 was applied throughout.  Descriptive statistics were used to 
describe the sociodemographic and clinical characteristics of the sample, as well as healthcare 
system and patient costs at each assessment point.  
To test the second objective, the associations between sociodemographic as well as 
clinical characteristics with total patient time and OOP costs were tested using t-tests and 
Pearson’s correlation, as appropriate. A general linear model was computed to test the 
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association of any significant characteristics, with adjustment for characteristics which differed 
by retention status. To test the final objective, patient time and OOP costs related to CR use 
specifically were described; this was followed by a comparison of these costs in CR completers 
versus dropouts.  
RESULTS 
Respondents Characteristics 
Figure 1 displays the flow of participants through the study. Table 1 displays participant 
sociodemographic and clinical characteristics pre-CR. As shown, there were some differences in 
the characteristics of participants retained at 2 years versus those lost-to-follow-up. With regard 
to sociodemographic characteristics, retained participants were more likely to self-report “North 
American” ethnocultural background compared to those lost to follow-up. No other differences 
were observed.   
Patient healthcare use and associated time and out-of-pocket costs 
Cardiac-related healthcare visits (i.e., costs to the healthcare system) participants reported 
at CR discharge, as well as at 1 and 2-year follow-up are shown in Table 3. Costs to the 
healthcare system were primarily related to visits to general practitioners, electrocardiograms and 
blood tests, as well as treatment of angina and other cardiac events (these were most commonly 
atrial fibrillation).  
Time and OOP patient costs (in Canadian dollars) related to this healthcare utilization is 
also shown in Table 3 by assessment point. As displayed, approximately 10% of patients 
required an accompanying person to aid them in attending their healthcare appointments. Patient 
costs in the first year were on average $410.08±391.68. Including OOP medication costs (see 
below), the average grand total cost to patients living with CVD for 2 years in a publicly-funded 
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healthcare system was $525.93±467.08 This represents 0.91% share of income spent by patients 
for non-CR cardiac care.  
Total costs for diagnostic interventions and medical procedures are reported in Table 3. 
As shown, total costs for healthcare visits and CVD procedures ranged from $44.41 to $209,697.  
In the CR discharge survey, 18 (16.8%) participants (who were not retired) reported 
difficulty working at their paid job because of their CVD. They reported having difficulty 
working 13.93±16.43 days, and that their work capacity was reduced by 65.00±26.29% during 
this time. With regard to unpaid work (e.g., household chores), 46 (20.0%) participants reporting 
requiring assistance since their event/procedure (regardless of work status). They required 
79.40±157.89 hours of assistance, and the cost for this was $856.43±2089.90 (median=340.00).  
Cardiac medication use, by class, in this cohort is reported elsewhere.16 Participants 
reported taking an average of 5.40±2.34 medications at 1 year and 5.01±2.32 at 2-year follow-
up. Mean OOP medication costs are shown in Table 3 by assessment point; the total OOP 
medication cost to patients over the 2 years following their event procedure was 
$271.86±324.77. Participants under the age of 65 (i.e., less likely to have some form of 
coverage) at study initiation reported spending $287.67±354.69 OOP on medication at 1 year, 
and $29.50±34.34 at 2 years. Figure 2a displays the breakdown of costs, including medications, 
in those working full-time for illustrative purposes.   
The association between participant sociodemographic and clinical characteristics and 
patient costs are shown Table 2. As expected, time costs were significantly higher for younger 
participants (i.e., time costs were only considered in participants who were working). OOP costs 
were significantly higher among female, unmarried, less educated patients than their male, 
married, more educated counterparts respectively; there was also a trend towards higher OOP 
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costs in obese patients. As shown, no other differences were observed.  A full model was tested, 
with adjustment for ethnocultural background as there was retention bias for this characteristic, 
of the association of age to time costs. The overall model was significant (F=3.75, p=.02), with 
age (F=5.11, p=.02) surviving this adjustment. A second full model was also tested, with again 
adjustment for ethnocultural background, of the association of sex, marital status, education and 
obesity to OOP costs. The overall model was significant (F=4.13, p<.01), with only a trend for 
sex (F=2.99, p=.09) and education (F=3.35, p=.07). 
Patient Costs Related to CR 
As shown in Figure 1, less than two-thirds of participants completed the CR discharge 
assessment and were considered to have completed CR; 60 (25.4%) of these participants were 
working full or part-time. Participants were on average prescribed 41.50±13.27 CR sessions by 
the program, and completed 25.80±16.66 sessions.  
They reported spending a mean of 44.82±51.81 hours (including travel) to participate in 
these sessions. The total patient cost to attend CR was $939.43±1333.29 (1.63% share of 1 year’s 
income; Given $25,163/year is considered a low-income in Canada 
[https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1110024101], the total patient cost would 
be 3.7% share of 1 year’s low income): $384.78±2269.67 OOP and $379.07±1035.49 on time 
associated with CR visits. Figure 2b displays the breakdown of costs, including CR, in those who 
are retired for illustrative purposes.  
DISCUSSION 
 In this first characterization of CVD patient costs in a publicly-funded healthcare system, 
results show that these are quite modest. OOP costs were somewhat higher than those reported 
by cancer survivors.6 The costs can be attributed to visits to general practitioners, for tests such 
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as electrocardiograms and bloodwork, and treatment for angina and atrial fibrillation, as well as 
medications. Workforce participation was not highly hindered by 6 months post-event/procedure. 
There were some potential drivers of patient costs however, suggesting women and less educated 
patients may have higher costs. Finally, the cost of CR participation to patients was shown to be 
double that for all other cardiac care over the 2 years.  
 That medication costs were lower over time could be explained by participants achieving 
the age of 65 and hence their medication costs may be covered by government or work benefits, 
or medication cessation due to excessive OOP costs. Optimal medical therapy is key to 
secondary prevention, and hence more investigation of the impact of OOP costs for medication 
on cardiac patient use and adherence is warranted.20,21,22  
Cardiac patients who were younger reported significantly higher costs, with a trend 
towards higher costs in women and less educated patients as well. The higher time costs in 
younger patients was a function of missing work to attend appointments. While reasons were not 
ascertained in this study, one could surmise that costs were higher for women as they often suffer 
from a higher burden of comorbidities than men.23 Reasons for higher OOP costs for less 
educated patients are likely socio-economic, as patients of lower socioeconomic means often 
have more severe disease, comorbidities and poorer outcomes. As less educated patients likely 
earn less money, it could also be the case that they were more likely to recall expenses related to 
their cardiac care, and to perceive them as greater, than their more educated, higher-income 
earning counterparts.  
 Participation in CR costs patients almost $1000CAD. Time costs in the HF-ACTION 
(Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training), a trial of 
exercise rehabilitation in heart failure patients were $1045USD (2008) for an average of 33 
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sessions requiring 53 hours.12 This is considerably higher than the findings reported herein 
(~$400), likely because no time cost was assigned to non-working patients. In the only Canadian 
study ever characterizing costs for CR participation to our knowledge,13 patients paid $99 (1987) 
OOP for travel and other expenses (not including time) to attend 16 sessions over 8 weeks. 
Considering inflation (purchasing power parity of $178 in 2017 Canadian dollars) and the greater 
number of sessions in which patients participated in the current study, this is considerably lower 
than the costs reported in the current cohort. Nevertheless, it is no wonder patients of low 
socioeconomic status are under-represented in CR programs,24,25 and that utilization rates overall 
are suboptimal.26,27,28  
Strategies to mitigate these costs to patients include a national pharmacare program (i.e., 
no out-of-pocket costs for medications), tele-healthcare,29 and home-based CR.30 Providing care 
to patients in their home contexts remotely may reduce costs to the healthcare system31 (although 
this is not the case for home-based CR which is equivalent in cost to delivering traditional 
supervised CR),32 and would discernibly reduce costs to patients as well.31 Reviews demonstrate 
equivalent outcome improvement with home32 and telehealth-based33,34 versus traditional 
supervised CR. At present, there is not broad availability of care via these means. 
Caution is warranted in interpreting these results.  First, given cost data was collected 
through self-report at fixed assessment points, inaccurate recall and recall failure may have 
biased results. In particular, there may have been more error associated with patient estimation of 
costs over the full second year of the study follow-up period. Second, time costs were computed 
using average provincial wages rather than actual income, as this information was not collected.  
On a related note, third, coverage for medications was not directly assessed. Assumptions were 
made based on age, so further research is needed to better understand cardiac patient OOP for 
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medications. Fourth, multiple comparisons were performed with regards to costs and time, 
increasing the chance of type 1 error. Fifth, there was some selection and retention bias in the 
sample, and there was much loss to follow-up. Sixth, generalizability is limited in several 
additional ways. Results are likely not very generalizable to other funding systems. In particular, 
patient costs for CR will vary widely by Canadian province given reimbursement policies differ, 
and as does prescribed CR dose.35,36 Moreover, results may not be generalizable outside major 
urban centers in Canada, as costs such as parking are likely higher in more densely-populated 
areas for example.  Finally, generalizability is further limited to patients who access CR. While 
CR is the standard of care for this population, only approximately 30% of patients access it.37 
Moreover, patients who attend CR are shown to be different than those who do not.38      
CONCLUSION  
Time and OOP costs were generally modest for cardiac patients over the course of their 
chronic disease, and would generally not represent a barrier to care. This excludes CR however, 
which cost almost double all their other cardiac care over 2 years combined. The heavy costs 
explain the low rates of CR use, particularly in those of low socioeconomic means. Alternative 
delivery approaches which reduce these costs must be delivered more broadly, so more patients 
access and complete these life-saving programs.  
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Figure 1. Participant Flow Diagram 
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Figure 2. Patient CVD-related costs by work status and cardiac rehabilitation participation from 
CR intake over 2 years 
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Table 1. Sociodemographic and Clinical Characteristics of Participants at Cardiac Rehabilitation 
intake by 2-year Survey Completion 
 
Characteristics  
Retained at 2 
years 
(n= 192, 46.7%) 
Lost to follow-
up 
 
(n=219, 53.3%) 
Total 
 
(N= 411) 
Sociodemographic 
Age† (mean years ± SD) 65.17 ± 9.32 63.82 ± 11.30 64.47 ± 10.42 
Sex† (% Male) 138 (71.9) 148 (68.5) 286 (70.1) 
Ethnocultural background (% North 
American) 
74 (46.5) 52 (33.1) 126 (39.9)* 
Marital Status (% married) 100 (77.5) 91 (71.7) 191 (74.6) 
Education (% < college/university)  74 (48.7) 69 (52.3) 143 (50.4) 
Work Status (% retired) 74 (47.7) 48 (52.7) 122 (51.5) 
Clinical  
Previous cardiac diagnosis (% yes) 7 (41.2) 12 (41.4) 19 (41.3) 
Peak METs§ (mean ± SD) 7.26 ± 2.93 7.08 ± 2.95 7.17 ± 2.94 
CR Referral Indication†    
PCI 72 (39.3) 81 (40.3) 153 (39.8) 
CABG 56 (30.8) 53 (26.4) 109 (28.5) 
Other  141 (73.4) 150 (68.5) 291 (70.8) 
Risk Factors†    
Dyslipidemia 86 (80.4) 86 (74.8) 172 (77.5) 
Hypertension 96 (81.4) 104 (81.3) 200 (81.3) 
Obesity 69 (39.9) 85 (44.7) 154 (42.4) 
Diabetes 31 (18.8) 46 (24.3) 77 (21.8) 
Current Smoker 10 (5.4) 0 (0.0) 10 (5.4) 
SD, standard deviation; CABG, Coronary artery bypass grafting; PCI, Percutaneous Coronary 
Intervention; MET, Metabolic Equivalent of Task.  
†source is medical chart (hospital or cardiac rehabilitation program) 
§from pre-CR graded exercise stress test. 
*p<.05 
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Caroline Chessex, MD, Rebecca Bassett-Gunter, PhD, Sherry L. Grace, PhD, Patient Satisfaction 
with Cardiac Rehabilitation: Association with Utilization, Functional Capacity, and Heart-Health 
Behaviors, 821-830., Copyright (2017), with permission from Dove Medical Press Ltd.[74] 
 
 
  
 35 
Table 2. Participant sociodemographic and pre-CR clinical characteristics, with associated time 
and out-of-pocket healthcare costs (N=411) 
 
Characteristics  
N (%) or 
mean ± SD 
Total Patient Time  
Cost○ 
($73.70±275.84) 
Total Out-of-Pocket 
Cost○ 
($377.01±321.72) 
Sociodemographic 
Age† (% <65 years) 207 (51.2) 147.18±398.27** 423.19±380.13 
          (≥65 years)    28.02±142.36 337.30±258.85 
Sex† (% Male) 287 (70.2) 76.89±302.36 314.41±239.97 
         (Female)  67.62±218.77  
 522.34±429.95*
* 
Self-reported Ethnocultural 
Background (% North 
American) 
126 (39.9) 81.89±243.32 364.66±335.01 
                      (Other)  36.88±131.15 405.34±343.72 
Marital Status (% married) 236 (74.7) 56.43±178.03 337.47±292.06 
                     (Other)  52.03±207.87 557.09±438.98* 
Education (% completed < 
college / university)  
160 (50.6) 42.13±178.98 504.43±413.62** 
                (≥ college / 
university) 
 70.91±194.51 283.17±215.30 
Work Status (% Full-Time / 
Part-Time) 
83 (35.2) 491.36±557.42 317.98±354.50 
                    (Other)  - 412.80±301.40 
Area of residence (% urban) 128 (31.1) 44.30±133.10 319.89±252.09 
                             (Suburban)  83.21±308.01 398.02±343.07 
Clinical 
Peak METs†§ǁ (mean ± SD at 
intake) 
7.17±2.93 0.08 -0.03 
Functional capacity‡ǁ (mean ± 
SD at discharge) 
25.10±10.28 0.07 -0.03 
CR Referral Indication†    
PCI (% yes) 153 (39.8) 43.79±123.92 409.76±342.56 
     (no)  91.40±337.70 330.56±297.06 
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CABG (% yes) 109 (28.5) 99.52±270.61 322.10±260.74 
           (no)  63.42±284.82 370.12±320.63 
Other (% yes) 211 (80.5) 48.84±133.55 362.73±324.92 
          (no)  143.35±590.03 527.54±274.17 
Risk Factors†    
Dyslipidemia (% yes) 293 (82.5) 60.33±272.29 359.35±310.75 
                       (no)  84.74±253.65 433.22±377.53 
Hypertension (% yes) 290 (76.9) 73.27±294.72 388.17±337.10 
                       (no)  80.34±244.44 329.66±255.80 
Obesity (% yes) 154 (42.4) 86.60±381.49 461.26±355.84†† 
                       (no)  72.61±215.20 325.91±296.75 
Diabetes (% yes) 77 (21.8) 126.19±499.13 394.84±210.21 
                       (no)  67.31±206.63 384.55±345.98 
Smoker (% yes) 11 (4.5)□ 81.23±161.23 234.11±170.96 
                       (no)  73.74±281.64 380.16±324.07 
Note: Due to missing data, percentages for each characteristic were computed using a 
denominator value specific to the sample size with complete data for that variable. 
Costs are reported in Canadian dollars. 
for test of association between characteristic and cost, using t-test or Pearson correlation as 
appropriate,  **p<.01; *p<.05; ††trend p<.10. 
SD, standard deviation; CABG, Coronary artery bypass grafting; PCI, Percutaneous Coronary 
Intervention; MET, Metabolic Equivalent of Task.  
- Participants who were not working were considered to have no time costs.  
†source is medical chart (hospital or cardiac rehabilitation program). ǂsource is medical chart 
and/or self-report. 
§from pre-cardiac rehabilitation graded exercise stress test. ‡from Duke Activity Status Index. 
ǁPearson’s r reported in this row for correlation with costs. ○Sum of CR discharge, 1 and 2 year 
costs.  
□inferential test not calculated due to small cell sizes.
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Table 3. Healthcare Utilization, Patient Time and Out-of-Pocket Costs by Time from CVD Diagnosis/Event 
Indicator CR Intake to 
Discharge / 6 
Months Later§ 
N=240 
CR Discharge / 6 
Months Later to 
 1 year  
N=178 
 1 year post-CR 
Intake to 2 years  
N=192  
Unit cost 
($)  
Total cost 
($) 
Healthcare Visitsǁ   
General 
Practitioner Visits 
(mean ± SD) 
2.13±2.38 3.21±3.40 2.64±2.09 77.20 (assessment) 
31 (subsequent visits) 
293.58 
CVD Specialist 
visits (mean ± SD) 
1.23±1.40 1.46±1.71 1.37±1.09 157.00 (consultation) 
31 (subsequent visits) 
251.86 
Emergency 
Department (mean 
± SD) 
0.15±0.53 0.29±0.91 0.17±0.55 97.60 59.53 
Hospital 
Admissions (mean 
± SD) 
0.08±0.39 0.13±0.53 0.06±0.24 79.90 21.57 
CVD Events and Procedures□ (n, %)   
Myocardial 
Infarction 
5 (2.9) 4 (1.5) 3 (2.5) 6,820 81,840 
Angina 22 (12.0) 13 (13.4) 19 (14.6) 3,671 198,234 
Percutaneous 
Coronary 
Intervention 
6 (3.5) 4 (4.2) 3 (2.5) 8,946 116,298 
Bypass Surgery 2 (1.2) 1 (1.0) 1 (0.8) 31,625 126,500 
Valve surgery  0 (0.0) 3 (3.1) 0 (0.0) 24,884 74,652 
Heart Failure  2 (1.2) 2 (2.1) 0 (0.0) 11,436 45,744 
Heart Transplant 0 (0.0) 0 (0.0) 0 (0.0) 130,298 130,298 
Left Ventricular 
Assist Device  
0 (0.0) 0 (0.0) 1 (0.8) 209,697 209,697 
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Rhythm Device 2 (1.2) 3 (3.1) 1 (0.8) 11,628 69,768 
Ablation 0 (0.0) 2 (2.1) 1 (0.8) 3,074 9,222 
Stroke 3 (1.7) 1 (1.0) 3 (2.5) 5,447 38,129 
Peripheral Vascular 
Disease  
0 (0.0) 1 (1.1) 2 (1.7) 6,264 18,792 
Other 21 (11.7) 9 (9.0) 13 (10.5) - - 
Cardiac Tests ǁ (n, %)   
X-Ray 43 (9.3) 50 (10.8) 60 (40.7) 32.65 4,995.45 
Electrocardiogram 95 (46.1) 121 (74.2) 118 (69.8) 11.05 3,690.70 
Blood Test 167 (76.6) 148 (89.2) 153 (87.4) 7.68 3,594.24 
Urine Test 68 (34.5) 98 (70.0) 106 (68.8) 4.30 1,169.60 
CT Scan 19 (10.4) 34 (29.1) 31 (23.7) 147.50 12,390 
Echocardiogram 50 (25.8) 87 (60.8) 83 (54.2) 208.80 45,936 
Stress Test 82 (40.6) 92 (59.7) 82 (53.9) 106.15 27,174.40 
Other 21 (11.6) 18 (16.2) 25 (19.7) - - 
Time & Out-of-Pocket Costs   
Cost for healthcare 
visits* (mean ± SD) 
$98.94±163.21 $79.03±88.32 $52.93±47.98 - - 
Accompanying 
person (% yes) 
39 (9.5) 41 (10.0) 57 (12.3) - - 
Accompanying 
person’s age (mean 
± SD) 
62.51±8.80 65.06±12.86 63.66±11.83 - - 
Accompanying 
person’s sex (% 
female) 
26 (52.0) 35 (49.3) 47 (62.7) - - 
Time† (mean ± SD 
hours) 
11.18±26.10 9.56±11.06 8.17±9.54 - - 
Medications  - $240.09±299.48a $25.95±30.47 - - 
Total time costǂ $72.37±306.14 $75.04±191.03 $72.70±168.52 - - 
Total out-of-
pocket cost  
$47.78±121.15 $272.40±275.58 $58.57±49.34 - - 
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Average total 
patient cost 
$123.74±341.43 $381.42±355.37 $157.11±205.10 - - 
Note: Due to missing data, percentages for each characteristic were computed using a denominator value specific to the sample size 
with complete data for that variable. 
Costs are reported in Canadian dollars. 
CVD, Cardiovascular Disease; SD, Standard deviation; CT, Computed tomography. 
*transportation, parking, food, lodging; including accompanying person where applicable. 
†for healthcare visits, including travel and waiting. ‡ household chores, caregiving, running errands.  
ǂ Total hours spent on health care visits were multiplied by the average hourly wages in 2016 in Ontario ($28.76/hour for those above 
the age of 55) working full-time. The hourly rate was halved for those working part-time. No time costs were considered for non-
working patients. 
§Assessment point 6 months post-initial CR visit. 
aRespondents were asked to report their medication costs in the previous 12 months, whereas all other values in this column were for 
the 6 months since the previous assessment, as per column header. 
ǁUnit costs were obtained from the Schedule of Benefits, Ministry of Health and Long-Term Care, 2015. 
□Unit costs were obtained from the Patient Cost Estimator tool developed by the Canadian Institute for Health Information 
https://www.cihi.ca/en/patient-cost-estimator
 40 
STUDY 2  
 
 
CERTIFICATE OF AUTHENTIFICATION 
 
Re: Funding Sources and Costs to Deliver Cardiac Rehabilitation around the Globe: 
Drivers and Barriers 
I hereby confirm that the first author of this manuscript, Mahshid Moghei, was 
responsible for quantitative analysis, the write-up of the manuscript, and drafting revisions for 
journal reviewers. Co-authors Turk-Adawi, Supervia and Lopez-Jimenez were collaborators 
from the global survey of cardiac rehabilitation programs, who were involved in study 
development and data collection, and provided minor editorial feedback just prior to submission. 
Co-author Schraa provided input from an economic perspective on the draft. Co-author Pesah 
was a master’s student in the lab who performed early data cleaning.  
 
 
 
Signature:                                                     Date:    March 20, 2019 
 
Signature:                                                                Date:   March 20, 2019 
 
 
 
 
 
  
 41 
Funding Sources and Costs to Deliver Cardiac Rehabilitation around the Globe: Drivers and 
Barriers 
 
ABSTRACT 
 
Background:  
 
Cardiac rehabilitation (CR) reach is minimal globally, primarily due to financial factors. This 
study characterized CR funding sources, cost to patients to participate, cost to programs to serve 
patients, and the drivers of these costs. 
Methods: 
 
In this cross-sectional study, an online survey was administered to CR programs globally. 
Cardiac associations and local champions facilitated program identification. Costs in each 
country were reported using purchasing power parity (PPP). Results were compared by World 
Bank country income classification using generalized linear mixed models.  
Results: 
111/203 (54.68%) countries in the world offer CR, of which data were collected in 93 (83.78% 
country response rate; N=1082 surveys, 32.0% program response rate). CR was most-often 
publicly funded (more in high-income countries [HICs]; p<.001), but in 60.20% of countries 
patients paid some or all of the cost. Funding source impacted capacity (p=.004), number of 
patients per exercise session (p<.001), personnel (p=.037), and functional capacity testing 
(p=.039). The median cost to serve 1 patient was $945.91PPP globally. In low and middle-
income countries (LMICs), exercise equipment and stress testing were perceived as the most 
expensive delivery elements, with front-line personnel costs perceived as costlier in HICs 
(p=.003). Modifiable factors associated with higher costs included CR team composition 
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(p=.001), stress testing (p=.002) and telemetry monitoring in HICs (p=.01), and not offering 
alternative models in LMICs (p=.02).  
Conclusions:  
Too many patients are paying out-of-pocket for CR, and more public funding is needed. Lower-
cost delivery approaches are imperative, and include walk tests, task-shifting, and intensity 
monitoring via perceived exertion.   
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INTRODUCTION 
 
Cardiovascular diseases (CVD) are among the leading burdens of disease and disability 
globally[1]. In addition to health impacts, CVD also poses a major economic burden on patients, 
society, and healthcare systems. On a global level, it is predicted that by 2030, the total cost of 
CVD will rise to a staggering $1,044 billion US dollars (USD) (from $863 billion USD in 
2010)[75]. Evidence suggests that CVD pushes approximately 10% of affected families into 
poverty in low and middle-income countries (LMICs) where the epidemic of CVD is at its 
worst[20].   
Cardiac rehabilitation (CR) is a chronic disease management program that successfully 
prolongs quality and quantity of life[7], and hence clinical practice guidelines recommend CVD 
patients participate[8,76]. The cost-effectiveness of CR is well-established across many contexts 
and perspectives[77–80]. CR participation is associated with return to work and healthcare 
avoidance. CR costs much less than percutaneous coronary intervention, yet equivalent outcomes 
are often achieved, supporting affordability[31]. 
Unfortunately, CR is grossly under-used[31]. While there are multiple factors at play[32], 
arguably the primary reason is financial. Most programs are under-resourced to deliver 
comprehensive evidence-based services. Indeed, surveys of CR programs in Australia and New 
Zealand[33], China[81], Japan[35], Scotland[82], Spain[37], Latin America and the 
Caribbean[38–40], the Arab Region as well as Canada[83] substantiate this.   
CR Coverage 
 
A major issue affecting financial viability of CR is whether services are reimbursed or 
“covered” by government or private insurers, among other sources. There is wide variation 
around the world in reimbursement sources however, and in many countries patients must pay 
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out-of-pocket (OOP). Recently, the International Council of Cardiovascular Prevention and 
Rehabilitation (ICCPR) surveyed CR leaders around the globe regarding reimbursement sources 
(respondents were asked to check all that apply); 61% reported the government, 55% reported 
patients pay OOP, and 52% reported insurance companies[19]. Clearly too many patients pay 
OOP for CR, and thus a better understanding of these costs is needed, given the likely impacts on 
utilization[84]. Indeed, the cost to patients to participate in CR has been scantly 
characterized[12–14].  
Delivery Costs 
 
Moreover, while financial resources are the major cause of under-utilization, little is 
known about the costs to deliver (quality) CR around the world. Most patients attend supervised 
programs located in clinical centres[10]; on average patients exercise on site 2-3 times per week 
for 5 months[11]. Most programs are staffed by a multi-disciplinary team, to ensure competent 
delivery of all core components for secondary prevention[85]. Hence, delivering the traditional 
model of CR carries with it costs associated with personnel, exercise equipment and other 
supplies, space and other operating costs[12,13,42].  
In only 14 (12.6%) of the 111 countries known to offer CR globally[86] are the costs to 
run a program per patient known, at a median of $884 USD (2016 PPP) in high-income countries 
(HICs)[87]. Where assessed, delivery costs were generally higher in private versus public 
healthcare systems. Moreover, CR is delivered at much lower cost in LMICs than in HICs, and 
what evidence is available suggests equivalent benefits are achieved[68]. Other than these, 
factors affecting delivery costs have never been examined to our knowledge. 
Therefore, the objectives of this study were to characterize: (1) funding source, and (1b) 
the proportion of the program cost as well as (1c) direct cost, to patients where they pay for CR; 
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and (2) the estimated cost to CR programs to provide service to 1 patient, (2b) which aspects of 
program delivery are perceived as most expensive, and (2c) whether cost varies by funding 
source in countries around the globe that deliver CR. The association of: (3i) a program’s patient 
capacity per year, (ii) the number and nature of healthcare professionals on the CR team, (iii) the 
number of patients served per exercise session (including staff-to-patient ratio), (iv) the number 
and nature of core components the program delivers; (v) the dose of CR (i.e., duration of 
program in weeks x the frequency of sessions per week); (vi) the equipment/resources the 
program has (e.g., exercise equipment, supplies for cardiovascular risk assessment) including 
whether patients are monitored during exercise using telemetry, and (vii) whether the program 
offers alternative CR models (i.e., home or community-based) to both funding source (1) and 
cost to treat 1 patient (2) will also be explored, to understand factors that impact CR delivery 
costs. Finally, (4) the degree to which financial and other resources serve as barriers to CR 
delivery will be described. Each will be compared by country income classification (i.e., HICs vs 
LMICs), and described in all countries of the world where CR is offered.   
METHODS 
 
Design & Procedure 
 
This research was observational and cross-sectional in design; detailed methods are 
reported elsewhere[86]. In brief, countries where CR services were available were identified first 
through previous reviews[31,84]. In countries where CR services were not suspected to be 
available, the internet was searched and major CR and cardiology societies were contacted to 
identify any programs or verify lack thereof.  
For each country identified to offer CR, first available CR or cardiac societies leadership 
was contacted, and if there was no society available or response, “champions” were identified. 
 46 
Identified leaders were sent an e-mail requesting their collaboration to administer the survey to 
each program in their country.  
The most responsible clinician at each program was emailed with the request to complete 
the survey. Informed consent was secured through an online form. The survey was administered 
through REDCap, with data collection occurring from June 2016 to July 2017. Contacts were 
sent 2 e-mail reminders, at 2 week intervals.  
Sample 
 
 The sample consisted of all CR programs identified in the world, that offer services to 
patients following an acute cardiac event or hospitalization (i.e., Phase II). This includes 
residential programs[88]. The inclusion criteria were CR programs that offered: (1) initial 
assessment, (2) structured exercise, and (3) at least one other strategy to control CV risk factors.  
Measures 
 
Development of the survey is described in detail elsewhere[83]. In short, items were 
based on previous national/regional CR programs surveys (e.g.,[10,39,89]). Most items had 
forced-choice response options, and skip-logic was used to obtain more detail where applicable. 
The survey is available elsewhere[86]. 
Respondents were asked to state their country. These were also categorized as high vs 
LMIC based on the World Bank classifications (http://data.worldbank.org/country). 
Cost-related items used herein included: who pays for CR (i.e., public sources such as 
government, private sources such as insurance companies or patients [and the amount they pay], 
or other sources), the cost to the CR program to serve one patient if they complete the program , 
perceived expense of various CR program elements, and resource-related barriers to CR delivery 
(the latter 2 were rated on a 5-point Likert-type scale). The drivers of costs were also assessed, 
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including: annual patient capacity, types of personnel on the CR team, staff-to-patient ratio 
during exercise sessions, and telemetry monitoring of patients, core components delivered, dose 
and alternative model delivery (i.e., home and community-based).  
Costs were reported using purchasing power parity (PPP), which is a widely used metric 
to compare different countries’ currencies with USD. PPP is an economic theory that compares 
different countries' currencies using a "basket of goods" approach. According to this concept, 
two currencies are in equilibrium when a basket of goods is priced the same in both countries, 
taking into account the exchange rates (Organization for Economic Co-operation and 
Development, Manual on Purchasing Power Parities). PPPs (2016) for each country were 
computed using a cost conversion tool developed by the Cochrane Economic group 
(http://eppi.ioe.ac.uk/costconversion/default.aspx).  
Data analysis  
 
SPSS version 24 was used for analysis[90]. All initiated surveys were included. The 
number of responses for each question varied due to missing data (e.g., respondent did not 
answer a question due to lack of willingness or potential inapplicability, use of skip logic); for 
descriptive analyses, percentages were computed with the denominator being the number of 
responses for a specific item.  
 Descriptive statistics were applied for all closed-ended items in the survey (i.e., objective 
1). All open-ended responses were coded / categorized. Associations were first tested on a 
univariate basis, using chi-square, t-tests, analysis of variance or correlations as appropriate.  
Costs and funding sources were then compared by World Bank country income 
classification, using generalized linear mixed models to take into consideration the multi-level 
nature of the data, to handle missing data and different distributions of the dependent variables. 
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Given variation in healthcare systems around the globe, country-level comparisons were not 
undertaken inferentially. 
RESULTS 
 
As reported elsewhere,[86] there were 111/203 (54.68%) countries in the world with CR, of 
which data were collected in 93 (83.78%). The number of responses (mean=9.74±17.26/ 
country), and response rate (32.07% overall) by country are also reported there. The total sample 
size was N=1082 surveys.  
Cardiac Rehabilitation Funding Sources 
 
CR funding source is shown by country in Figure 1. Overall, in 46 (49.46%) countries CR was 
most often paid by public sources (i.e., government, hospital), in 22 (23.66%) countries CR was 
paid by private sources (i.e., patients or private healthcare insurance), and in 25 (26.88%) 
countries CR was paid by a combination of these sources. Some respondents also listed other 
sources, which included research (n=8 programs), fundraising/charity foundations (n=4), and 
veteran services (n=3).  
CR was significantly more often paid by public (n=489, 66.40%) sources in HICs than in 
LMICs (n=103, 31.70%, p<0.001). Accordingly, CR was less often paid by private (n=87, 
11.80%) and hybrid (n=161, 21.80%) sources in HICs than in LMICs (n=115, 35.30%; p<0.001; 
and n=107, 33.10%; p<0.001 respectively).  
 For the countries where patients paid some or all of the program cost (n=56, 60.20%), the 
mean proportion of the program cost and the amount they paid are shown in Table 1. Patients in 
Kenya and the Philippines paid all of the cost in most programs; patients pay all the cost in some 
programs in Greece, Pakistan, Peru and New Zealand. The cost to the patient was the highest in 
the following countries (PPP2016): Greece, Spain and Mexico (as well as Tunisia, but with only 
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1 response caution is warranted). The proportion of the program that patients paid (p=0.19) nor 
the direct cost to patients (where they pay) for CR (p=0.79) were not significantly different in 
HICs than in LMICs. 
 Table 2 shows aspects of CR programs that are associated with funding source. As 
shown, program capacity (greater with hybrid sources), healthcare providers on team (greater 
with public than private funding), individual consult with physicians (greater with private 
funding), cardiopulmonary stress testing (greater with private funding), and patients per exercise 
session (greater with public and hybrid than private funding) varied significantly by funding 
source. When testing each of the 10 core components individually, tobacco cessation (p<0.001), 
return-to-work counselling (p=0.02), and patient education (p<.01) were significantly more-
commonly offered with public funding. While funding source was not associated with delivery 
of CR in any alternative setting, programs with public funding more often offered community-
based CR specifically than privately-funded ones (p=.03). No other associations were observed. 
Finally, Table 2 also shows that program capacity (higher where patients paid), the number of 
healthcare providers on the CR team (lower), and number of core components delivered (lower 
where patients paid) were also significantly different based on whether patients paid for at least 
some of program costs or not.  
 
Costs to Deliver CR 
 
 The estimated cost to deliver a full CR program to one patient is shown in Table 1. This 
did not differ significantly in LMICs versus HICs. Costs were highest in the following HICs: 
Bermuda, Austria, United States; costs were lowest in Chile, Uruguay and Singapore. Costs were 
highest in the following LMICs: Republic of Northern Macedonia, Dominican Republic, and 
Venezuela; costs were lowest in Cuba, Pakistan and Indonesia.  
 50 
 The elements of CR that contribute to these costs are shown in Table 4. As shown, in 
HICs, front-line personnel and exercise stress testing were perceived as most expensive and in 
LMICs, exercise equipment and exercise stress testing were perceived as most expensive. Front-
line personnel was considered significantly more expensive in HICs than LMICs (p<0.01); no 
other differences were observed.   
 Drivers of costs in HICs and LMICs are shown in Table 3. In HICs, program delivery  
costs significantly varied by funding source (i.e., higher with public and hybrid than private, and 
no patient finding versus any), were significantly higher with greater program capacity (and 
volume; data not shown), more providers on the healthcare team, higher where there was a 
physician on the CR team and patients had an individual consult with said physician, patients 
undergo cardiopulmonary stress tests, more core components are delivered, and patients are 
monitored with telemetry during exercise. In LMICs, higher program delivery costs were 
similarly associated with greater program capacity and with a greater number of providers on the 
healthcare team (trend for physicians specifically), but also with fewer patients per exercise 
session, and were significantly lower where programs offered alternative CR models (e.g., 
unsupervised). There was only a trend for funding source. 
Degree to Which Financial Resources Are Barriers to Cardiac Rehabilitation Delivery  
Finally, the perceived degree to which financial factors impede greater CR provision is 
reported by country[91] and by country income classification elsewhere[92]. When compared by 
funding sources, human resources, space and equipment were greater delivery constraints with 
public funding compared to private funding (Figure 2).  
 
Nature of CR Services in Canada 
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Program responders were asked to report who pays for their services, and could check all 
applicable sources (n =27,37.0% reported >1 source). Figure 3 displays the most common 
funders of CR by province/territory. Nationally, 41 (56.2%) reported hospital/clinical centre 
funding (with significant provincial variation, P= 0.02), 32 (43.8%) programs reported 
government funding, 23 (31.5%) reported the patient pays (and when they do they pay for on 
average 33.4% ±35.7% of the program, or CAD$253.10 ±235.24), 6 (8.2%) reported private 
health insurance, and 9 (12.3%) reported other funding sources (these included fund raising, a 
University and the Young Men’s Christian Association (YMCA); all n =1, 1.4%). In 4 (5.5%) 
programs, the sole source of funding was the patient. The funding source in Canada was not 
different than other HICs (P=0.43). 
It is important to highlight that in Canada, the proportion of CR program costs incurred 
by patients is 33.23% ± 38.66. The direct cost to patient is $275.29 ± $194.68 and cost to deliver 
CR to 1 patient is $938.29 ± $563.81.  
DISCUSSION 
 CR funding and costs have been characterized globally for the first time herein. Of the 
countries with CR in the world (just over half), CR was funded from public sources solely in 
half, and this was more common in HICs (consistent with the fact that there is more public 
funding of health systems in HICs than LMICs[93]). Funding source impacted delivery costs, 
program capacity, patients per session, number and nature of healthcare providers on the team, 
and types of functional testing used. Moreover, some key CR components that would likely 
result in greater return-on-investment and downstream cost-savings (e.g., return-to-work and 
tobacco cessation counselling) were significantly more-commonly offered with public funding. 
CR resource availability, investment and care quality should not be impacted by funding source.  
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In almost 2/3rds of the countries with CR, patients are paying for some or all of their CR 
programs OOP (on average 50% of the program cost or over $600USDPPP2016). This would 
lead to greater under-utilization. Given more patients in LMICs pay OOP than HICs, yet there is 
no significant difference in the proportion of the program costs paid or the amount in LMICs vs 
HICs (which likely reflects the fact that healthcare is more expensive in HICs[93]), this 
represents an especially heavy burden on patients in LMICs where economic well-being is 
significantly lower.  
The estimated cost to deliver CR to 1 patient, which should indeed be considered a gross 
estimate at this stage, was consistent in high LMICs (~$1500 2016PPP). Whether this represents 
a sufficient investment for effective CR remains to be established. These costs varied in relation 
to CR personnel composition, including physicians who are generally more expensive. 
Cardiopulmonary stress testing and telemetry monitoring increased costs in HICs and alternative 
models reduced them in LMICs. The main costs associated with CR delivery were for exercise 
equipment, human resources and exercise stress testing, with most of these factors impeding CR 
delivery to a much greater degree in programs with some public funding. In LMICs, higher 
volume of patients per exercise session was associated with cost efficiencies.  
The $1500PPP cost to deliver CR is considerably lower than percutaneous 
intervention[94,95], which is sometimes performed without benefit when compared to optimal 
medical therapy. Moreover CR results in less healthcare utilization and more return-to-work, 
which further economically benefits society, adding further value to the low delivery cost. The 
only other available data on overall program costs[87] stem from the HICs of Canada ($884 
2016USDPPP)[13] and Australia ($1312 2016USDPPP)[12]. In the former, while human 
resource and equipment costs were high, space figured more prominently, as it did in the 
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Australian study (although they considered some unit costs not assessed herein such as 
“administration” and “technology” which should be considered in future research). The available 
literature on CR personnel costs specifically is reviewed elsewhere[87]. Given the multi-
component nature of CR, and hence the multiple disciplines required to deliver it 
comprehensively, personnel costs are understandably quite high. There is wide variation in the 
staffing complement of CR programs, as well as program policies around staff-to-patient ratios 
during exercise for safety[45,46,83]; correspondingly overall costs to programs would vary. In 
LMICs, exercise equipment is considered the most expensive aspect of program delivery. As per 
the International Council of Cardiovascular Prevention and Rehabilitation (ICCPR) consensus 
statement on CR delivery in low-resource setting, low-cost alternatives for exercise equipment 
are put forward[96,97], which should be seriously considered based on these findings.  
In many LMICs (55.32% of those with CR), the cost of CR delivery is higher than the 
mean health expenditure per capita (although we concede this is a crude comparison, but it does 
reflect affordability and relative investment). This would be an even higher percentage if we 
considered revascularization, yet we would not argue it should not be delivered, and therefore we 
need to consider how CR can be delivered in a safe, high-quality manner while containing costs. 
In addition to the suggestions to keep costs down in ICCPR’s consensus statement[96,97] and 
our previous review[87], based on the findings herein, strategies to reduce costs that should be 
tested include task-shifting to less expensive personnel (e.g., community healthcare workers), 
using physicians for consultation purposes as needed only, using a cheaper functional test than a 
cardiopulmonary stress test such as a 6 minute walk or shuttle walk test[98], exercising more 
patients per session, delivering exercise through non-equipment-based modalities, and not 
monitoring patients with telemetry during exercise unless they are established as high-risk. But 
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more research is needed as we do not know how these factors may impact program quality or 
safety. 
Limitations 
Caution is necessary when interpreting the findings, particularly due to limits on 
generalizability. Firstly, response rates to online surveys are notoriously low. While 
generalizability to countries with CR can be considered high, extrapolation within some 
countries should be undertaken with caution due to low program response rates. Second, it may 
not have been possible to identify programs, especially in LMICs where they may not have a 
website or have published any research, and in countries where no society or champion was 
identified. Therefore, extra caution should be taken when generalizing results from these 
countries.  
The final limitation relates to measurement. Costs were self-reported and in most cases 
likely estimated, such that there is likely much measurement error. Moreover, there are no 
international accounting standards for program-level costing. Therefore, it was not considered 
appropriate to compare costs across countries (moreover given the variation in disease burden 
and severity, the likely variation in CR dropout rates, etc. by country). The cost items in the 
survey were not sufficiently detailed to capture what types of costs respondents included in their 
estimates (e.g., capital, overhead, how human resource costs are partitioned on a per patient 
basis). Additionally, costs were likely considered differently depending on the health system in a 
given country (e.g., budgeted values, charges or billing data, or actual total or marginal costs). 
However the $1500PPP cost is consistent with delivery costs in Canada and the United Kingdom 
for example, and hence the data appear reasonable. Future research is needed to better 
characterize unit costs of CR delivery globally. On a related note, mean healthcare expenditure 
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values used to put the costs in context were not available post-2014, yet data were collected in 
2016.  
CONCLUSION 
 Where available, CR is most often funded by public sources, but in 60% of programs, 
patients pay all or part of the cost OOP (on average half of the program cost or over $600PPP). 
The $1500 cost to treat one patient was driven primarily by personnel, exercise equipment and 
exercise stress testing costs, and varied by funding source in HICs. Funding source was also 
related to program capacity, patients per session, number of personnel (including physicians), 
and the type of functional capacity test used. Public (including hybrid) funding for CR had 
distinct advantages. Task-shifting, use of functional walk tests, exercising more patients per 
session, not monitoring with telemetry and offering CR in unsupervised settings can reduce 
costs; safety of such approaches warrant testing on a large-scale.  
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Figure 1. Most Common Cardiac Rehabilitation Funding Source by Country, Including Patients.  
 
  
• Patients pay some or all of costs 
   Country has no CR  
 
CR, Cardiac Rehabilitation 
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Figure 2. Degree to which financial resources serve as barriers to cardiac rehabilitation delivery 
by funding source† 
 
 
*p<.001. 
Rating scale from 1=“not an issue” to 5 “major issue”.  
 †shown by country income classification elsewhere[92].  
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Figure 3. Most common cardiac rehabilitation funding source by province/territory 
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Table 1. Patients Paying for CR, as well as Cost to Deliver CR Juxtaposed by Mean Healthcare Expenditure Per Capita, by Country 
with CR and Country Income Classification, N=1082 
Income Classification 
Country 
n Proportion of 
Program Cost 
Patient Pays  
(Mean ± SD %) 
Direct Cost to Patient 
(2016 PPP†) 
Mean ± SD 
Cost to Deliver CR to 
1 Patient (2016 
PPP†)§ 
Mean ± SD 
Healthcare Expenditure 
per Capita in 2014 
PPP[99] (CR proportion)  
High-Income      
Australia 85 37.33 ± 54.42 $144.88 ± $280.41 $1023.99 ± $602.76 $6031.11 (16.98%) 
Austria 5 _ _ $5668.26 ± $421.90 $5580.49 (101.57%) 
Bahrain 1 0 NA _ $1242.84 
Barbados 1 0  NA _ $1146.04 
Belgium 9 9.70 ± 6.83 $317.77 ± $231.50 $1951.81 ± $945.05 $4839.83 (40.33%) 
Bermuda 1 _ _ $7,073.00 n/a 
Canada 55 33.23 ± 38.66 $275.29 ± $194.68 $938.29 ± $563.81 $5291.74 (18.58%) 
Chile 1 50.00  $100.00  $100.00  $1137.35 (8.79%) 
Croatia 3 17.00 ± 0.00 $73.44 ± 0.00 $346.40 ± $158.28 $1050.33 (32.98%) 
Czech Republic 6 50.00 ± 0.00 $185.82 $3493.38 $1378.52 (253.42%) 
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Curaçao  1 _ _ $586.00  _ 
Denmark 1 0 NA $1960.53  $6463.24 (30.33%) 
Estonia 2 0 NA $938.63 ± $0.00 $1248.28 (75.19%) 
Finland 11 0 NA $984.66 ± $894.82 $4612.29 (21.34%) 
France 16 0 NA $4598.05 ± $2066.49 $4958.99 (92.72%) 
Germany 34 12.82 ± 25.97 $734.14 ± $700.61 $2427.81 ± $977.11  $5410.63 (44.87%) 
Greece 4 100.00 ± 0.00 $3114.75 ± $231.84 $1967.21 ± $1614.57 $1743.04 (112.85%) 
Hungary 20 0 NA $1467.41 ± $183.66 $1036.62 (141.56%) 
Iceland 4 56.00 ± 26.51 $309.45 ± $152.01 $2369.77 ± $3754.25 $4661.62 (50.84%) 
Ireland 6 0 NA $716.33 ± $0.00 $4239.15 (16.90%) 
Israel 6 15.00 ± 21.21 100.00 $1450.00 ± $1100.00 $2919.29 (49.67%) 
Italy 68 47.20 ± 39.64 $1675.00 ± $2238.71 $4375.73 ± $2111.61 $3257.75 (134.32%) 
Japan 9 0 NA $396.00 ± $434.46 $3702.95 (10.69%) 
Latvia 1 13.00  $262.10  $2096.77  $920.70 (227.74%) 
Lithuania 9 0 NA $1400.29 ± $467.15 $1063.42 (131.68%) 
Netherlands 29 15.00 _ $1662.51 ± $1297.79 $5693.86 (29.20%) 
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New Zealand 27 100.00 ± 0.00 $491.19 ± $129.35 $557.81 ± $740.05 $4896.35 (11.39%) 
Northern Ireland 10 0 NA $859.60  n/a 
Poland 20 0 NA $1507.98 ± $810.68 $910.28 (165.66%) 
Portugal 20 53.20 ± 44.17 $694.99 ± $1277.56 $789.93 ± $610.14  $2096.82 (37.67%) 
Qatar 1 0 NA _ $2106.35 
Russian Federation 3 0 NA _ $892.85 
Scotland 23 60.00  _ $778.65 ± $502.25 $3934.82 (19.79%) 
Singapore 7 45.00 ± 37.75 $263.87 ± $247.23 $226.37 ± $93.86 $2752.32 (8.22%) 
Slovak Republic 1 95.00 $374.22  $374.22 $1454.81 (25.72%) 
Slovenia 2 75.00 $383.97 $1277.13 ± $1263.11 $2160.75 (59.11%) 
South Korea  12 98.18 ± 6.03 $681.03 ± $445.72 $820.20 ± $429.63 $2060.25 (39.81%) 
Spain 47 _ $2470.06 ± $740.98 1679.14 ± $1466.69 $2658.27 (63.17%) 
Sweden 1 0 NA _ $6807.72 
Switzerland 4 _ _ $1601.83 ± $1189.05 $9673.52 (16.56%) 
Taiwan 22 9.83 ± 1.36 $151.53 ± $45.11 $894.14 ± $775.41 n/a 
United Kingdom 57 66.5 ± 47.37 $157.59 $731.54 ± $220.07 $3934.82 (18.59%) 
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United States 65 15.78 ± 8.45 $1272.00 ± $2291.59 $5016.60 ± $2723.11 $9402.54 (53.35%) 
Uruguay 5 75.00 ± 28.87 $722.56 ± $1035.39 $148.16 ± $97.73 $1442.27 (10.27%) 
Wales 15 _ $35.82  $1002.87 _ 
HIC Mean ± SD  40.67 ± 38.87 $675.49 ± $1178.54 $1865.48 ± $1857.57 $3420.37 ± $2315.79 
HIC Median  
(Q25-Q75) 
 20.00  
(10.00-86.25) 
$244.86  
(142.40-595.66) 
$1267.10  
(580.63-2427.04) 
$2835.81  
(1345.96-4912.01) 
Low and Middle-
Income 
     
Afghanistan 1 0 NA _ $56.57 
Algeria 1 _ _ _ $361.73 
Argentina 3 75.00 ± 35.35 $47.50 ± $10.61 $1200.00 $605.19 (198.28%) 
Bangladesh 1 20.00  $336.38  $336.38  $30.83 (1091.08%) 
Belarus 1 0 NA _ $450.21  
Bosnia and Herzegovina 1 20.00  $175.95  $879.77  $463.64 (189.75%) 
Brazil 29 77.5 ± 36.15 $1262.22 ± $453.69 $844.57 $947.43 (89.14%) 
Brunei Darussalam 2 0 NA _ $957.60 
 
 
68 
Bulgaria 1 0 NA _ $661.85 
China 81 40.82 ± 30.00 $618.37 ± $672.60 $706.75 ± $734.16 $419.73 (168.38%) 
Colombia 47 14.33 ± 7.68 $132.92 ± $141.53 $833.96 ± $597.59 $569.18 (146.52%) 
Costa Rica 6 _ $867.38 ± $802.39 $300.00  $970.00 (30.93%) 
Cuba 8 0 NA $45.28 $816.62 (5.54%) 
Dominican Republic 1 15.00  _ $3549.61  $268.99 (1319.60%) 
Ecuador 2  _ $450.00  $900.00 ± $848.53 $579.19 (155.39%) 
Egypt 2 20.00 $150.00 _ $177.77 
Georgia 11 83.75 ± 29.61 $749.86 ± $540.81 $729.53 ± $284.76 $302.60 (241.09%) 
Guatemala 2 10.00 $89.57 _ $232.62 
Honduras 1 _ _ $300.00  $212.31 (141.30%) 
India 18 90.78 ± 23.87 $357.61 ± $195.55 $1027.12 ± $2030.27 $74.99 (1369.68%) 
Indonesia 9 21.67 ± 25.66 $541.20 ± $327.06 $276.05 ± $14.21 $99.41 (277.69%) 
Iran 14 29.82 ± 18.08 $249.16 ± $343.18 $1906.88 ± $2947.68 $350.74 (543.67%) 
Jamaica 1 _ _ _ $266.19 
Kazakhstan 1 _ _ _ $538.78 
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Kenya 1 100.00  $1598.30  $1598.30  $77.69 (2057.28%) 
Lebanon 1 80.00  $1000.00  $1000.00  $568.71 (175.84%) 
Republic of Northern 
Macedonia 
1 _ _ $6116.21 $353.92 (1728.13%) 
Malaysia 4 25.00 ± 22.91 $255.63 ± $72.30 $749.83 ± $379.53 $455.82 (164.50%) 
Malta 1 0 NA _ $2470.59 
Mauritius 1 _ _ _ $482.45 
Mexico 9 84.17 ± 29.39 $2400.41 ± $1919.58 $1808.92 ± $1955.39 $677.19 (267.12%) 
Moldova 1 0 NA $944.80  $228.85 (412.85%) 
Morocco 1 _ _ _ $190.05  
Mongolia 1 _ _ _ $195.33 
Nepal 1 0 NA _ $39.87 
Nigeria 1 90.00 _ _ $117.52 
Pakistan 2 100.00 $171.35  $171.35 $36.15 (473.99%) 
Panama 1 _ $108.00  _ $958.98 
Paraguay 3 50.00 $325.00 ± $247.49 $400.00 $464.09 (86.19%) 
Peru 7 100.00 $1584.28 $883.39 ± $991.20 $358.58 (246.36%) 
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CR, cardiac rehabilitation; SD, standard deviation; USD, United States Dollars; Q25-Q75, 1st- 3rd quartile  
§this item assessed total program costs (i.e., not itemized) and hence was likely estimated grossly by respondents. Therefore 
there is likely considerable measurement error which should be taken into consideration when interpreting the values. 
†PPP, Purchasing Power Parity (http://eppi.ioe.ac.uk/costconversion/default.aspx) 
- Response about CR cost was not provided by any respondent in the country  
Philippines 10 100.00 ± 0.00 $764.27 ± $297.64 $485.60 ± $198.47 $135.20 (359.17%) 
Romania 2 _ _ $532.94 $556.81 (95.71%) 
Serbia 2 0 NA $868.71 ± $354.25 $632.92 (137.25%) 
South Africa 14 53.00 ± 41.91 $1251.08 ± $1063.39 $1716.99 ± $1474.63 $570.21 (301.11%) 
Sri Lanka 1 0 NA _ $127.33 
Tunisia 1 66.00  $2853.07  $2139.80  $305.30 (700.88%) 
Turkey 9 0 NA $1549.36 ± $576.87 $567.63 (272.95%) 
Venezuela 8 85.00 ± 23.80 $391.50 ± $256.95 $2972.29 ± $1978.09 $873.38 (340.32%) 
LMIC Mean ± SD  49.60 ± 38.30 $597.25 ± $783.03 $1038.26 ± $1202.81 $455.39 ± $401.28 
LMIC Median  
(Q25-Q75) 
 35.00  
(11.50-100.00) 
$338.28  
(100.60-814.21) 
718.23  
(337.33-1232.43) 
$390.73  
(194.01-572.45) 
Global Mean± SD  46.13 ± 38.70 $626.07 ± $946.33 $1527.84 ± $1671.11 $1803.11 ± $2166.96 
Global Median 
 (Q25-Q75) 
 30.00  
(11.50-100.00) 
$295.42 
(119.64-711.045) 
$945.91  
(438.89-1940.42) 
$901.57  
(357.41-2517.51) 
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NA – not applicable as patients do not pay for any part of CR in this country 
n/a not available 
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   Table 2. Impact of Cardiac Rehabilitation Funding Source 
 
n (%) or mean ± standard 
deviation Public Only 
Private Only 
(insurance or 
patient) 
Hybrid All  Any Patient Funding 
Program capacity (patients / 
year) 
522.46 ± 887.86 
ǁǁ 
534.46 ± 923.20 
† 
     
   926.98 ± 1661.00 
ǁǁ 
† 
627.32 ± 1151.93 
** 
     
768.41 ± 1473.59 
* 
 
        Median (Q25-Q75)§ 273.00  (120.00-510.00) 
200.00  
(100.00-580.00) 
400.00 
 (200.00-900.00) 
300.00  
(120.00-600.00) 
300.00  
(128.00-700.00) 
Number healthcare providers on 
team  
5.97 ± 2.72 
† 
5.25±2.54 
† 
6.15 ± 3.10 
 
5.88 ± 2.81 
* 
5.61 ± 2.82 
** 
Physician on team (% yes) 210 (40.50%)  80 (46.20%) 124 (52.80%) 414 (44.70%) 174 (49.00%) 
Staff-to-patient ratio 
 
1:5.15 ± 9.45 1:3.52 ± 3.19 
 
1:5.07 ± 7.31 
 
1:4.81 ± 8.04 
 
1:4.29 ± 6.11 
 
      Median (Q25-Q75) 1:4.00  
(3.00-5.25) 
 
1:3.00  
(2.00-4.62) 
1:4.00  
(2.83-5.00) 
1:4.00  
(2.50-5.00) 
1:3.60 
 (2.00-5.00) 
Patient receives individual 
consult with physician (% yes) 
271 (60.0%) 
† 
130 (81.80%) 
† 
ǁ 
151 (70.20%) 
ǁ 
552 (66.80%) 
** 
246 (75.70%) 
Program uses cardiopulmonary 
stress tests (VO2) 
352 (68.20%) 138 (77.50%) 
† 
 
162 (68.10%) 
† 
 
652 (70.00%) 
* 
266 (74.30%) 
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Number risk factors assessed 
(/12) 
8.48 ± 3.59 8.35 ± 3.69 8.79 ± 3.52 8.54 ± 3.59 8.87 ± 3.29 
Core components delivered (/10) 7.24 ± 2.98 6.93 ± 2.92 7.33 ± 2.83 7.21 ± 2.93 7.27 ± 2.64 
** 
Patients monitored during 
exercise with telemetry (% yes) 
244 (48.70%)  97 (57.10%) 170 (73.00%) 511 (56.50%) 236 (67.00%) 
Patients per exercise session 9.95 ± 5.75 
††† 
6.10 ± 5.41 
††† 
ǁǁǁ 
9.28 ± 5.31 
ǁǁǁ 
 
9.04 ± 5.76 
*** 
7.80 ± 5.59 
     Median (Q25-Q75) 9.00 (6.00-12.00) 5.00 (2.00-8.00) 8.00 (5.00-12.00) 8.00 (5.00-12.00) 6.00 (4.00-10.00) 
CR dose (hours) 33.09 ± 48.70 42.11 ± 55.07 41.05 ± 60.11 37.03 ± 53.27 40.77 ± 53.71 
     Median (Q25-Q75) 18.00  
(10.37-36.00) 
 
28.00  
(18.00-45.00) 
30.00  
(18.33-41.95) 
24.00  
(12.00-36.00) 
30.00  
(18.00-45.00) 
Program offers alternative 
models (% yes) 
194 (38.60%) 38 (22.10%) 51 (21.80%) 283 (31.20%) 81 (22.80%) 
§median and 1st- 3rd quartile (Q25-Q75) shown where variation high (i.e., standard deviations greater than means). 
Compared by funding source using Generalized Linear Mixed model adjusting for country – one model for each row.  
* p<.05; ** p<.01; *** p<.001 for Generalized Mixed Models testing for overall model significance  
†ǁ 1 symbol p<.05; 2 symbols p<.01; 3 symbols p<.001 for pairwise comparisons  
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Table 3. Drivers of Program Delivery Costs, by Country Income Classification 
 
Driver 
n (%) or  
mean ± standard deviation (median) 
High-Income 
(n=749) 
p† Low or Middle-
Income 
(n=333) 
p† 
Funding source ($2016PPPǁ)  0.003  0.07 
   Public $1981.20 ± 1962.69  
($1306.73) 
 $1262.69 ± 1275.21 
($1012.04) 
 
   Private (incl. patients) $1051.22 ± 963.02 
($582.66) 
 $1200.29 ± 1291.33 
($828.13) 
 
  Hybrid $2084.86 ± 1898.54 
($1513.24) 
 $780.38 ± 1036.84 
($517.65) 
 
          Patients (full or partial) 184 (24.90%) <0.001 211 (65.30%) 0.35 
 Yes $1399.21 ± 1554.68 
($797.87) 
 $998.77 ± 1207.05 
($641.64) 
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 No $2054.81 ± 1939.76 
($1408.45) 
 $1176.54 ± 1199.78 
($998.29) 
 
Program capacity (patients / year) 537.48 ± 809.79 
(300.00) 
0.005 806.56 ± 1623.82 
(300.00) 
<0.001 
Number healthcare providers on team§ 5.91 ± 2.78 (5.50) 0.001 5.81 ± 2.85 (5.50) 0.002 
Physician on team (% yes) 227 (36.30%) 0.006 188 (61.20%) 0.06 
      Yes $2486.99 ± 1914.59 
($1960.53) 
 $1168.82 ± 1403.41 
($731.48) 
 
      No $1158.00 ± 1403.94  
($716.33) 
 $798.66 ± 678.37 
($568.64) 
 
Staff-to-patient ratio 1:5.45 ± 9.58  
(1:4.00) 
0.19 1:3.51 ± 2.69 
(1:3.00) 
0.52 
Patient receives individual consult with physician (% yes) 303 (54.30%) 0.001 253 (93.00%) 0.85 
     Yes $2158.57 ± 1905.31 
($1668.08) 
 $980.50 ± 1095.68 
($702.22) 
 
     No $1190.50±1602.96  $822.38 ± 786.76  
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($716.33) ($474.55) 
Program has cardiopulmonary stress tests (VO2) (% yes) 403 (63.50%) 0.002 253 (83.80%) 0.33 
     Yes $1942.74 ± 1774.64 
($1440.64) 
 $1098.10 ± 1288.65 
($836.35) 
 
     No $1281.36 ± 1806.42 
($716.33) 
 $810.01 ± 773.99 
($585.19) 
 
Core components delivered (/10) 8.23 ± 1.59 
(8.50) 
0.01 7.68 ± 1.75 
(8.00) 
0.87 
Patients monitored during exercise with telemetry (% yes) 341 (56.10%) 0.01 172 (57.00%) 0.26 
   Yes $2199.64 ± 2050.47 
($1445.78) 
 $943.72 ± 1040.08 
($701.94) 
 
   No $1147.22 ± 1043.09 
($828.50) 
 $1126.70 ± 1384.41 
($718.23) 
 
Number patients per exercise session 9.68 ± 5.55 
(8.50) 
0.71 7.77 ± 6.08 
(6.00) 
<0.001 
CR dose (hours) 35.93 ± 57.44 0.87 39.65 ± 43.51 0.68 
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(22.50) (30.00) 
Program offers alternative models (% yes) 219 (36.00%) 0.38 66 (21.50%) 0.02 
   Yes $1588.30 ± 1867.82 
($800.00) 
 $684.68 ± 605.38 
($431.41) 
 
   No $1956.69 ± 1790.90 
($1516.44) 
 $1122.69 ± 1305.00 
($731.48) 
 
ǁ PPP, Purchasing Power Parity (http://eppi.ioe.ac.uk/costconversion/default.aspx) 
§part-time staff counted as .5.   
†association with cost to deliver CR to 1 patient, using generalized linear mixed model adjusting for country.  
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Table 4. Perceived expense of elements to deliver cardiac rehabilitation 
 
Mean ± Standard Deviationǁ 
High-Income 
(n=747) 
Low or Middle-Income 
(n=335) 
All 
(N=1082)§ 
Front-line personnel 3.51 ± 1.25 2.83 ± 1.10 3.29 ± 1.24** 
Exercise equipment 3.13 ± 1.21 3.49 ± 1.24 3.25 ± 1.23 
Exercise stress testing  3.21 ± 1.33 3.27 ± 1.17 3.23 ± 1.28 
Equipment/supplies for CVD risk assessment  2.84 ± 1.12 3.10 ± 1.20 2.93 ± 1.15 
Space 2.76 ± 1.32 2.85 ± 1.28 2.79 ± 1.30 
Patient education material 2.29 ± 0.89 2.36 ± 0.97 2.31 ± 0.92 
Blood pressure assessment device 2.27 ± 0.82 2.16 ± 0.93 2.23 ± 0.86 
Blood collection and lipid testing 2.42 ± 1.00 2.63 ± 1.03 2.50 ± 1.02† 
Resistance training equipment  2.44 ± 0.91 2.56 ± 0.98 2.48 ± 0.93 
CVD, Cardiovascular disease 
ǁscores range from 1=“free” to 5=”very expensive” 
***p<.01.  
†trend, p=.08 
§ Compared by country income classification using generalized linear mixed model adjusting for country – one model for each 
row.  
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Table 5. Cardiac rehabilitation funding source by province/territory 
 
Province CR Funding Source 
n (%) 
 
Government Hospital Patient Insurance Other 
Alberta 1 (100%) -- -- -- -- 
British Columbia  1 (14.3%) 4 (57.1%) 5 (71.4%) -- 3 (42.9%) 
Manitoba 1 (100%) -- 1 (100%) -- -- 
New Brunswick 1 (50%) 2 (100%) -- -- -- 
Newfoundland & 
Labrador 
1 (50%) -- -- -- 1 (50%) 
Nova Scotia -- 1 (100%) -- -- -- 
Ontario 10 (38.5%) 20 (76.9%) 6 (23.1%) 5 (19.2%) 2 (7.7%) 
PEI 1 (100%) -- -- -- -- 
Quebec 4 (66.7%) 3 (50%) 1 (16.7%) -- -- 
Saskatchewan 6 (35.3%) 8 (47.1%) 6 (35.3%) 1 (5.9%) 2 (11.8%) 
North  -- No CR -- -- -- -- -- 
Canada  25 (45.5%) 33 (60%) 17 
(30.9%) 
5 (9.1%) 6 (10.9%) 
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STUDY 3  
 
Promoting Exercise Maintenance Post-CR 
Exercise maintenance post-CR remains a challenge. Numerous studies have reported that 
CR graduates are failing to maintain adequate levels of physical activity (PA) (150 minutes of 
moderate/vigorous physical activity weekly)[1–3] despite education and counselling in 
CR[4],[5]. Willmer et al.[6] compared how PA at one and five years post-CR varied in patients 
that had engaged in an exercise maintenance program versus those that had not. Regardless of 
their membership in an exercise maintenance program, both groups engaged in fewer minutes of 
PA (maintenance program at 1 and 5 years [140 and 120 minutes per week respectively], no 
maintenance program at 1 and 5 years [138 and 105 minutes per week respectively]), and less 
frequently met the recommended 30 minutes of PA per day.   
Given PA declines, interventions to increase PA levels post-CR have been tested. To 
date, there have been 10 published RCTs of interventions to improve exercise maintenance post-
CR[7–15]; 8 of these RCTs have shown beneficial results[7–9], [12–15]. Interventions that 
improved PA levels or helped maintain CR induced benefits (e.g., improvements in 
cardiometabolic fitness), incorporated a mix of self-regulatory skills training on exercise 
planning;[13] exercise consultation;[8] an exercise diary and quarterly group meetings;[7] a 
home walking program and daily activity log [10]; written action and coping plans[14,15]; and 
self-monitoring of vital measurements, and pedometer-measured PA with personal feedback.[9]  
Only one study was undertaken in Canada; it did not improve exercise maintenance 52 weeks 
post-CR.[11] 
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There are substantial limitations to the literature assessing interventions for exercise 
maintenance. One of the most critical limitations is the lack of an economic evaluation; previous 
studies[7,10,13,16] that have assessed interventions for maintenance of PA levels did not 
consider incorporating community resources for exercise to facilitate sustainability and 
affordability.  
One strategy to promote exercise maintenance post-CR is the use of an exercise facilitator 
intervention via telephone. Our randomized controlled trial of post-CR participants[17], 
ecologically optimizing exercise maintenance in men and women post-cardiac rehabilitation 
(ECO-PCR), assessed costs for implementing an exercise facilitator intervention for 52 weeks. 
Participant characteristics of the sample is shown in Table 1. The intervention employed a single 
face-to-face introduction between the participant and facilitator, small group counseling 
teleconferences, personal telephone contacts, and community exercise program demonstrations 
(where desired). The facilitator helped participants develop plans for adhering to their exercise. 
Small group counseling teleconferences were held 3, 13, 26, 39 and 50 weeks after 
randomization. At each session, participants reviewed their activity diaries, identified barriers to 
exercise maintenance experienced and brainstormed solutions as a group. 
The facilitator contacted participants individually by telephone 20, 34 and 45 weeks after CR 
program completion. During each telephone call, the facilitator reviewed the participant's activity 
diary and assessed their confidence and motivation with respect to exercise maintenance. 
Data was collected on resources used to deliver the intervention, including training time 
for facilitators; phone equipment and long distance charges for teleconference counseling, 
workbooks and pedometers. Costs were derived by multiplying the quantities of resources used 
by their appropriate unit costs. The total cost for teleconference counselling was $2645.64, 
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parking pass for patients cost $5,500 and the pedometers cost $974. Phone equipment was 
included in the overhead clinical costs; therefore, it was not a cost to the study. 
Facilitator training took 15 hours. Intervention delivery required 5.6 facilitator hours per 
participant. Out of the 9 facilitator sessions offered to each patient, on average 7.50±2.23 calls 
were attended (4.02±1.41 /5 group calls and 2.66±0.79 /3 personal calls). The overall 
intervention cost, as shown in Table 1, was $29,320.18 Canadian dollars (CAD); this averaged to 
$129.73 CAD per patient.  
Of note in the ECO-PCR intervention, we did try to exploit existing community exercise 
facilities but few to no participants took advantage of this (n=49, 16.10% engaged in physical 
activity at a facility recommended by the rehab program; n=37, 12.10% went to a “heartwise 
exercise program”; n=9, 3.00% attended an Alumni/ maintenance program; n=134, 44.10% 
engaged in community physical activity in other places), therefore this is not an avenue to pursue 
for our population. 
The intervention was only effective at promoting PA maintenance in women adherent to it, 
therefore, a full analysis of whether the intervention is cost-effective is not warranted. Among 
women adherent to the intervention, the group in whom the intervention was proven effective, 
PA intentions at 26 weeks were significantly greater in the intervention arm (p=.04), with no 
other differences. There were some differences in socio-ecological elements associated with 
MVPA by arm. There were also some differences by sex, with MVPA more often associated 
with exercise benefits/barriers in men, versus with working and the physical environment in 
women. However, in future, it should be considered whether effective post-CR exercise 
interventions are associated with less downstream healthcare utilization and hence could be cost-
saving.  
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Although previous interventions did not consider costs, it is expected that one-to-one 
exercise consultations with a trained professional are costly. Therefore, other low-cost strategies 
to promote exercise maintenance post-CR must be considered. Of the effective interventions 
previously tried, the CHANGE intervention[12] might be particularly low-cost. The intervention 
consisted of five small group sessions of counselling and behaviour modification based on 
several cognitive-behavioural theoretical frameworks. An experienced cardiac nurse delivered 
three 1.5-hour sessions once a week during the last three weeks of CR and two sessions at 1- and 
2-months post CR. The costs of delivering the intervention were approximately $30 per 
participant (nurse salary and teaching materials). 
Other ideas not yet tried in CR graduates include the use of a lifestyle-focused text 
messaging service, smartphone applications and incentive-based rewards. Text messaging has 
been shown to result in improvements in lifestyle and risk factor modification in CVD 
patients[18]. Moreover, a recent study showed that providing very small but immediate rewards 
for daily step goal achievement, as part of a multi-component intervention, increased daily step 
counts on a population scale[19]. Participants earned incentives in the form of loyalty points 
(worth Can $0.04) every day they reached their personalized daily step goal (ie, baseline 
mean+1000 steps=first daily step goal level). Participants could earn up to Can $5.00 during the 
12-week evaluation period. Although this study was not in CVD patients, it could be tested post-
CR.  
Unfortunately, there have not been any studies on the cost-effectiveness of interventions 
to promote exercise post-CR. Also, the duration of effects and whether or not these interventions 
result in less downstream healthcare utilization remain to be determined.  
 
CONCLUSIONS 
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CVD patients incur modest time and OOP costs over the course of their disease. The high 
OOP costs of CR are particularly a challenge in those with low socioeconomic status. Many 
patients are paying OOP for CR services, therefore, alternative approaches of CR delivery are 
needed to reduce costs in addition to more public funding. Strategies to reduce CR delivery costs 
include the use of walk tests, task-shifting, and intensity monitoring via perceived exertion. 
Long-term maintenance of exercise behaviour remains a challenge in CVD patients. Maintaining 
and enhancing physical activity levels is imperative for patients to protect their cardiovascular 
health following CR. Further research is needed to determine the effectiveness of exercise 
maintenance interventions more importantly their cost. Once established, low-cost interventions 
that result in improvements in exercise behaviour maintenance in CVD patients must be 
incorporated into CR practice guidelines and disseminated to programs.  
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Table 1: Background Characteristics of the ECO-PCR Sample  
 Female Participants Male Participants 
 Intervention 
(n=68) 
Usual Care 
(n=67) 
Intervention 
(n=158) 
Usual Care 
(n=156) 
Background and demographics     
Age, mean (SD), y 65.3 (10.3) 66.1 (10.5) 63.0 (9.8) 63.2 (9.4) 
White, n (%) 55 (80.9) 56 (83.5) 124 (78.4) 118 (75.6) 
Married or cohabiting, n (%)  33 (48.5) 34 (50.7) 114 (72.1) 115 (73.7) 
Employed full-time, n (%) 14 (20.5) 10 (14.9) 46 (29.1) 47 (30.1) 
Current smoker, n (%) 1 (1.5) 1 (1.5) 2 (1.2) 3 (2.0) 
Body mass index, mean (SD), 
kg/m2 
27.0 (5.1) 28.9 (5.7) 29.0 (4.8) 28.3 (4.8) 
Medical History     
Hypertension, n (%) 36 (52.9) 47 (70.1) 94 (59.5) 83 (53.2) 
Dyslipidemia, n (%) 33 (48.5) 48 (71.6) 99 (63.9) 99 (63.5) 
Diabetes mellitus, n (%) 13 (19.1) 14 (20.8) 28 (17.7) 29 (18.5) 
Prior cardiac history, n (%) 7 (10.3) 5 (7.5) 15 (9.5) 24 (15.4) 
PVD, n (%) 2 (2.9) 2 (3.0) 4 (2.5) 1 (0.6) 
Heart failure, n (%) 0 (0.0) 1 (1.5) 1 (0.6) 2 (1.3) 
Chronic kidney disease, n (%) 1 (1.5) 0 (0.0) 4 (2.5) 4 (2.6) 
LVEF, % 57.5 (9.0)  59.8 (7.3) 51.8 (11.7) 54.3 (11.2) 
Indication for CR     
CABG, n (%) 12 (17.6) 17 (25.4) 48 (30.4) 39 (25.0) 
PCI, n (%) 43 (63.2) 38 (56.7) 102 (64.6) 100 (64.1) 
MI, n (%) 36 (52.9) 30 (45.5) 78 (49.7) 71 (45.8) 
Angina, n (%) 6 (9.1) 10 (15.6) 10 (6.8) 13 (9.0) 
Medications     
ACE inhibitor, n (%) 33 (48.5) 33 (49.3) 92 (58.2) 83 (53.2) 
Angiotensin receptor blocker, n (%) 14 (20.6) 18 (26.9) 13 (8.3) 15 (9.6) 
Beta-blocker, n (%) 49 (72.1) 54 (80.6) 121 (76.6) 121 (77.6) 
Calcium channel blocker, n (%) 13 (19.1) 11 (16.4) 19 (12.0) 24 (15.4) 
Diuretic, n (%) 7 (10.3) 10 (14.9) 17 (10.8) 9 (5.8) 
Diabetes medication, n (%) 6  (8.8) 11 (16.4) 28 (17.7) 21 (13.4) 
Nitrates, n (%) 24 (35.2) 32 (47.8) 63 (40.1) 55 (35.3) 
Aspirin, n (%) 60 (88.2) 60 (89.6) 149 (94.3) 149 (95.5) 
Other anti-platelet medication, n 
(%) 
29 (42.6) 25 (37.3) 65 (41.1) 60 (38.5) 
Psychotropic medication, n (%) 14 (20.6) 16 (23.9) 15 (9.6) 15 (9.6) 
Statin, n (%) 60 (88.2) 61 (91.0) 151 (95.6) 145 (92.9) 
SD, standard deviation; PVD, pheripheral vascular disease; LVEF, left ventricular ejection fraction; 
CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention; MI, myocardial 
infarction 
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Table 2 
Micro-costing from healthcare perspective for the intervention group 
 
Item Unit Price  Total Cost  
Training Exercise 
Facilitator (Includes 
training and patient call 
times) 
$25.41 $22,329.04 
Teleconference Calls $220.47 $2645.64 
Pedometer Costs $13.00 $1755.00 
Workbook Costs $23.55 $2590.50 
 
Note: amounts shown in Canadian dollars. 
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Appendices 
Appendix A 
Study 1 Informed Consent Form 
 
 
 
 
CONSENT TO PARTICIPATE IN A RESEARCH STUDY 
  
STUDY NAME:  Cardiovascular Rehabilitation—Chronic Disease Management 
Program Evaluation and Cost-Effectiveness Analysis 
 
INVESTIGATORS:   
 
Sherry L. Grace, PhD (Principal Investigator) York University and University Health 
Network 
Caroline Chessex, MD (Co-Principal 
Investigator) 
University Health Network  
 
Doug S. Lee, MD (Co-Investigator) Institute for Clinical Evaluative Sciences 
and University Health Network 
Harindra Wijeysundera, MD (Co-Investigator) Sunnybrook Health Sciences Centre and 
University of Toronto 
Mansoor Husain, MD (Co-Investigator) University Health Network 
 
You are being asked to take part in a research study. Please read this explanation about the study 
and its risks and benefits before you decide if you would like to take part. You should take as much 
time as you need to make your decision. You should ask the study doctor or study staff to explain 
anything that you do not understand and make sure that all of your questions have been answered 
before signing this consent form. Before you make your decision, feel free to talk about this study 
with anyone you wish. Participation in this study is voluntary. 
  
Background and Purpose 
 
You have already agreed to participate in the University Health Network Cardiovascular 
Rehabilitation and Prevention Program. In this research study, we would like to better understand 
how quality of life in our participants with atrial fibrillation changes following participation in CR.  
 
Study Design and Procedures 
 
As a patient who has had atrial fibrillation, you will be asked to complete 2 surveys online: one 
at the beginning of the cardiovascular rehab program, and one at the end. The survey includes 
questions about your symptoms, how you participate in activities, and any concerns about your 
treatment. The survey takes about 5 minutes to complete. 
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Finally, we would also like your permission to link your survey responses with the information 
gathered as part of the cardiac rehab program for the Canadian Cardiac Rehab Registry. This would 
not require any paperwork on your behalf.   
 
Voluntary Participation 
 
Your completion of both surveys is voluntary. If you consent to participate in this study, your 
survey responses would be used for research purposes.  
 
You may decide not to be in this study, or to be in the study now, and then change your mind later. 
You may leave the study at any time without affecting your current or future care. 
 
Potential Benefits and Risks  
 
You may not receive any direct benefit from being in this study. Information learned from this 
study may help other people with your condition in the future.  
 
There are no additional risks to you if you take part in this study. Being in this study may make 
you feel uncomfortable. You may refuse to answer questions if there is any discomfort. 
 
As a general reminder, email may not always be a secure method of communication. For this 
study, email is being used for general communication purposes only, and will not be used to 
collect/provide personal health information.  If you take part in this study, please be reminded 
that personal information will be collected in a de-identified manner through the online survey. 
 
Confidentiality  
 
If you agree to join this study, the study doctor and his/her study team will look at your personal 
health information and collect only the information they need for the study. Personal health 
information is any information that could be used to identify you and includes your: 
• name,  
• email address, 
• address,  
• OHIP number, new or existing medical records, that includes types, dates and results of 
medical tests or procedures.   
 
A list linking your study number with your name will be kept by the study doctor in a secure place, 
separate from your study file. 
 
The information that is collected for the study will be kept in a locked and secure area by the study 
doctor for 10 years. Only the study team or the people or groups listed below will be allowed to 
look at your records.   
 
Representatives of the University Health Network Research Ethics Board may look at the study 
records and at your personal health information to check that the information collected for the 
study is correct and to make sure the study followed proper laws and guidelines. 
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We are collaborating with some other programs in the country. Therefore, parts of the 
information you provide in your survey may be securely and anonymously shared with the 
research investigators from this larger study.  
 
Please note that any information that you provide for this study in the online survey, even though 
de-identified, when transferred to the U.S, is subject to U.S. laws, and in particular, to the U.S. 
Patriot Act. The US Patriot Act allows authorities access to the records of study participants in 
the event of auditing by authorities. 
 
All information collected during this study, including your personal health information, will be 
kept confidential and will not be shared with anyone outside the study unless required by law.  You 
will not be named in any reports, publications, or presentations that may come from this study.   
 
If you decide to leave the study, the information about you that was collected before you left the 
study will still be used.  No new information will be collected without your permission.  
 
Costs 
 
You will not have to pay for any of the procedures involved with this study. You will not be 
reimbursed for completing the survey. 
 
Conflict of Interest 
 
Researchers have an interest in completing this study. Their interests should not influence your 
decision to participate in this study. 
 
Questions About the Study 
 
Feel free to speak to one of our staff members if you have any questions or concerns.  
 
If you have any questions about your rights as a research participant or have concerns about this 
study, call the Chair of the University Health Network Research Ethics Board (UHN REB) or the 
Research Ethics office number at 416-581-7849. The REB is a group of people who oversee the 
ethical conduct of research studies. The UHN REB is not part of the study team. Everything that 
you discuss will be kept confidential. 
   
CONSENT 
 
o This study has been explained to me and any questions I had have been answered. I know 
that I may leave the study at any time. I agree to take part in this study.  
 
Date: ____________________ 
Appendix B 
Study 1 Patient Survey  
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Instructions for completing the survey questions appear at the beginning of 
each section. 
 
Please return your completed survey in the paid-postage return 
envelope. 
Cardiovascular Rehabilitation—Chronic Disease 
Management Program Evaluation 
 
 
12 Month Follow-up  
Survey 
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SECTION H: USING MEDICAL CARE  
 
We would like to know about the health professionals you saw during the last 12 months 
BECAUSE OF YOUR CARDIOVASCULAR HEALTH. It will be easier to answer if you 
refer to a calendar or appointment list on which you record your appointments. If you did not 
keep a record, try to remember if any appointments were on or near special days, such as your 
birthday, or the day of a social event. Please answer the questions below by entering the number 
of times in the past 12 months that you have: 
 
  Number of times  
1. Seen your family doctor 
 
________ 
2. Seen a heart specialist 
 
________ 
3. Gone to the Emergency Department  
 
________ 
4. Been admitted to the hospital  
 
________ 
 
5. Have you experienced any of the following heart problems or procedures in the last 12 
months? (Please check þ all that apply): 
q Heart Attack          
q Angina          
q Angioplasty (stent)    
q Bypass Surgery           
q Valve Surgery           
q Heart Failure  
q Heart transplant  
q Pacemaker or implantable cardioverter defibrillator 
q Stroke  
q Peripheral Vascular Disease 
q Ablation 
q Left ventricular assist device 
q Other, please specify: ______________________________________ 
q None of the above 
 
6. Have you experienced any of the following diagnostic tests in the last 12 months? (Please 
check þ all that apply):  
q X-Ray 
q Electrocardiogram (ECG) 
q Blood test 
q Urine test 
q CT Scan 
q Echocardiogram 
q Stress Test 
q Other, please specify: ______________________________________ 
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q None of the above 
 
7. How much of your own money, in total, did you pay for these health care visits (eg., 
transportation, parking, food, lodging), including the money paid by anyone who 
accompanied you?  
q None       OR enter amount:    $_________ 
    
8. How much time was associated with these health care visits (include travel, waiting, etc.)?  
 
________hours in total 
 
9. In the last 12 months, who USUALLY accompanied you on these health care visits? Check 
(Ö) all that apply.  
q Nobody; I usually went by myself 
q Partner 
q Son, daughter, or grandchild 
q Sister, brother, friend, or neighbour 
q Volunteer 
q Paid homemaker or caregiver 
q Other, please specify_____________________________________ 
 
9b. This person’s age is: ___________years.   
 
9c. This person is:   c Male  OR    c Female 
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SECTION K: YOUR MEDICATIONS 
 
Please record all medications, prescribed by a health professional or bought over-the-counter, 
that you used DURING THE LAST 8 MONTHS FOR CARDIOVASCULAR HEALTH.  
Include medications taken for heart disease and its problems (e.g., pain), or problems caused by 
treatment (e.g. loss of sexual function).  
 
Write the dose used each time (e.g. two 5 mg pills=10 mg) and the number of times used each 
day. If you used it less often than once per day (e.g., an injection once every 4 weeks), please 
write this in the space after "Times taken/used per day". If you used more than 6 medications, 
please write them on the back page.  
We suggest that you put the medications you have at home in front of you while you answer 
these questions. Remember to include herbal medicine, skin creams, drops, needles, etc., as well 
as pills. 
 
q I used NO medications during the last 12 months. 
                                                                                      
1. Medication: _______________________________________ 
 
Dose (each time taken/used) :________    Times taken/used per day:________  
 
2. Medication: _________________________________________________ 
 
Dose (each time taken/used) :_______      Times taken/used per day:________     
 
3. Medication: _______________________________________________ 
 
Dose (each time taken/used) :_______     Times taken/used per day:_______      
 
4. Medication: ______________________________________________________ 
 
Dose (each time taken/used) :_______     Times taken/used per day:________   
 
5. Medication: ________________________________________________ 
 
Dose (each time taken/used) :________     Times taken/used per day:______ 
 
    6. Medication: _________________________________________________ 
 
Dose (each time taken/used) :_______   Times taken/used per day:__________      
 
   7. Medication: _________________________________________________ 
 
Dose (each time taken/used) :_______   Times taken/used per day:__________      
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8.  How much of your own money did you spend in the last 12 months, with no   
        reimbursement, for all of your medications?      
 
$ _________________ 
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Appendix C  
CR Global Survey Informed Consent Form 
 
 
 
 
 
GLOBAL CARDIAC REHABILITATION PROGRAM SURVEY 
 
Consent form 
 
You are being asked to participate in a research study to understand the availability and 
characteristics of cardiac rehabilitation programs globally. You are being asked to participate 
because you are the most responsible clinician or administrator of a cardiac rehabilitation 
program.  
 
What You Will Be Asked to Do in the Research:  
If you agree to participate, you will be asked to respond to an online survey that takes about 20 
minutes to complete.  
Data will be collected primarily via online survey. Phone or paper administration may be 
possible in some instances if you do not have internet access and are willing to provide your 
information in this manner.  
 
Confidentiality: 
All information you supply during the research will be held in confidence, and your name will 
not appear in any report or publication of the research.  
 
Your data will be safely stored. Each completed survey will only be identifiable by a unique 
research identification number. Electronic survey responses will be stored on a secure database. 
It will not be stored on any portable media. Only the research team will have access to the 
collected information. The Principal Investigators will destroy the data 15 years after the 
completion of the project: the electronic database will be deleted from the system. 
Confidentiality will be provided to the fullest extent possible by law. 
 
Benefits of the Research and Benefits to You:  
This research is designed to understand the availability of cardiac rehab, particularly in low- and 
middle-income countries where there is a growing burden of cardiovascular disease. We hope to 
use the findings to inform policy in international and national fora, on the status of and gaps in 
cardiac rehabilitation.  
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If you are interested, we will provide you with comparative information about the characteristics 
of other cardiac rehabilitation programs in your country or region. This information may be of 
use to you in advocating for CR services in your region. 
 
You will not receive payment for your participation. 
 
 
Risks and Discomforts:  
We do not foresee any risks or discomfort from your participation in the research. You may 
refuse to answer any question(s) that you do not wish to answer.  
 
Voluntary Participation:  
Your participation in the study is voluntary and you may choose to stop participating at any time. 
Your decision not to volunteer will not influence the nature of the ongoing relationship you may 
have with the researchers, or study staff, or the nature of your relationship with York University 
of the Mayo Clinic either now, or in the future. You have the right to withdraw your consent or 
discontinue participation at any time without penalty.  
 
Questions About the Research?  
If you have questions about the research in general or about your role in the study, please feel 
free to contact Dr. Sherry Grace  
 
This research has been reviewed and approved by the Human Participants Review Sub-
Committee, York University's Ethics Review Board, and conforms to the standards of the 
Canadian Tri-Council Research Ethics guidelines. If you have any questions about this process 
or about your rights as a participant in the study, please contact the Sr. Manager & Policy 
Advisor for the Office of Research Ethics, 5th Floor, York Research Tower, York University. In 
addition, if you have any concerns, complaints, or general questions about research or your rights 
as a participant, please contact the Mayo Institutional Review Board (IRB) to speak to someone 
independent of the research team at 507-266-4000 or toll free at 866-273-4681.  
 
Legal Rights and Consent: 
 
I consent to participate in "Global Cardiac Rehabilitation Survey: Availability and 
Characteristics of Programs" conducted by Drs. Sherry Grace & Francisco Lopez. I have 
understood the nature of this project and wish to participate. I am not waiving any of my legal 
rights by completing this form. My checkmark below indicates my consent. 
 
 
q I consent  
 
 
Today's date: ______________________ (dd/mmm/yyyy) 
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Appendix D  
Global CR Program Survey 
 
CARDIAC REHABILITATION PROGRAM QUESTIONNAIRE 
 
 
1. What is your Title/Position at the cardiac rehabilitation program? (check Pone): 
c Director 
c Coordinator / Manager / Supervisor 
c Clinician, specify: __________________________ 
c Other, specify: __________________________________________________ 
 
SECTION A: GENERAL INFORMATION  
 
2. In what country is your cardiac rehabilitation program? ______________ 
3. City / Region: ___________________(optional) 
4. Your cardiac rehabilitation program is located in an: 
  Urban area (e.g.larger cities, towns) 
  Suburban (a residential district located on the outskirts of a city) 
  Rural area or countryside (a geographic area that is located outside towns and 
cities). 
 
5. In what year was your cardiac rehabilitation program initiated? _______ (year) 
6. Who pays for cardiac rehabilitation ? (Check all that apply)  
c Social security / government 
c Hospital or  clinical center where the cardiac rehab service is based  
c Patient (answer 6b & c)        
c Private health insurance  
c Other (specify): _____________________  
 
6b. What is average percent of the total program cost that patients pay, if they complete the 
program?  
 
_____ %             OR     □ I don’t know 
       6c. What is the direct cost to patients to participate, if they complete the program?  
 
_____________    ___________  OR     □ I don’t know 
Amount   currency 
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7. Is your cardiac rehabilitation program located within a hospital (check Pone)?  
c Yes – it is in a referral centre/ quarternary / tertiary facility and / or academic centre 
c Yes – it is in a community hospital 
c Yes -  it is in a rehabilitation hospital/ residential facility  
If checked: Is your CR program a spa/residential program?  □ Yes    □ No 
c Yes – other (please specify: _______________________________________) 
c No (skip to question 10) 
 
8. If Q7 was marked yes, does the hospital have an inpatient cardiology service?  Check one 
box:  
c Yes, and these patients are referred to our cardiac rehabilitation program regularly 
c Yes, and these patients are sometimes referred to our cardiac rehabilitation program 
c Yes, and these patients are rarely referred to our cardiac rehabilitation program  
c No    
 
9. If Q7 and Q8 were marked yes, do they offer? (check all that apply) 
c Revascularization via percutaneous coronary intervention (PCI)  
c Coronary artery bypass graft surgery (CABG)  
c Percutaneous valve implantation 
c Implantable heart devices (pacemakers or defibrillators) 
c Cardiac transplant 
c None 
 
10. In what department is the cardiac rehabilitation program situated administratively? 
  Cardiology department 
  Physical Medicine and Rehabilitation department 
  Internal Medicine department 
  Primary / general practice 
  It is in a community facility 
  None – it is stand-alone 
  Other (specify) :_________________________ 
 
11. For patients referred following a cardiac hospitalization, on average how many weeks after 
discharge does a patient start your program? (i.e., initial assessment appointment)  
     
__________ weeks 
 
12. How many unique cardiac rehabilitation patients do you provide service to each year in your 
program?  
 
_________ patients per year  
 
 
13. How many patients do you have capacity to serve each year, in terms of staff and space?  
_____________ patients per year   
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14. What is the cost to your program to serve one (1) patient, if they complete the program?  
 
_____________    ___________  OR     □ I don’t know 
Amount   currency 
 
15. Who can refer a patient to your program? Check all that apply 
c Patients can self-refer 
c Physicians 
c Allied healthcare providers and / or nurses 
c Community health care workers 
c Other, please specify: ___________________________________ 
 
16.  Are there any other Cardiac Rehabilitation programs in your area? Check one box 
c Yes, within approximately a 20 km radius 
c Yes, but more than 20 km away 
c None  
c I don’t know 
 
17. Please rate the degree to which each of the following are barriers to greater patient 
participation in your cardiac rehab program, from “this is definitely not an issue” to “this is 
a major issue”: Check one per row. 
 
This is definitely 
not an issue 
1 
This is not 
an issue 
2 
Neutral 
3 
This is a minor 
issue 
4 
This is a 
major issue 
5 
 
 
Lack of patient referral      
 
Lack of equipment  
(specify:______) 
     
 
Lack of space      
 
Lack of human resources      
 
Lack of financial resources/ 
budget 
     
 
Other (specify:____________)       
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SECTION B: DETAILS ABOUT YOUR CARDIAC REHABILITATION PROGRAM 
 
18. Who has overall responsibility for cardiac rehabilitation at your program? Please check one 
box:  
c Cardiologist 
c Physician specialist in internal medicine 
c Physical medicine and rehabilitation (physiatrist) 
c Physician, other specialty (please specify: _______________________________) 
c Nurse 
c Exercise physiologist 
c Physiotherapist  
c Other (specify)_________________________ 
 
19. How expensive are the following aspects of delivering your cardiac rehab program? (check 
one box per row) 
 
 Free Only a 
minor 
cost 
Costs 
a bit 
costs 
quite 
a bit 
Very 
expensive 
Not 
applicable 
as we do 
not have 
this 
a. Front-line personnel       
b. Space       
c. Exercise equipment       
d. Equipment / supplies for 
cardiovascular risk assessment 
(not including exercise stress 
tests) 
      
e. Exercise stress testing on a 
treadmill or cycle ergometer 
      
f. Patient education materials       
g. Blood pressure assessment 
device 
      
h. Blood collection and lipid 
testing 
      
i. Free weights etc. for resistance 
training 
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20. Which of the following components of cardiac rehabilitation are provided in your program? 
If they are provided, are they provided in all the models you deliver? (i.e., supervised and 
home-based programs)?  
 
Please check one box per row. If you only offer one model of rehabilitation and you offer the 
listed component, please check “yes, in all models”.  
 Yes  
In all 
models 
Yes 
For some 
models 
No 
Initial assessment    
Individual consultation with a physician    
Individual consultation with a nurse    
Exercise stress test    
Other functional capacity test (please specify:  
_______________________________) 
   
Assessment of strength (e.g., handgrip)     
Assessment for comorbities / issues that could 
impact exercise (e.g., cognition, vision, 
musculoskeletal / mobility issues, frailty, and / 
or balance / falls risk) 
   
Exercise prescription    
Physical activity counseling    
Supervised exercise training    
Heart rate measurement training for patients     
Resistance training     
Management of cardiovascular risk factors    
Prescription and/or titration of secondary 
prevention medications 
   
Nutrition counseling    
Depression screening    
Psychological counseling     
Smoking cessation sessions/classes    
Vocational counseling / support for return-to-
work 
   
Stress management / Relaxation techniques    
Alternative forms of exercise, such as yoga, 
dance, or tai chi (please specify: ___________) 
   
Women-only classes    
End of program re-assessment    
Electronic patient charting    
Communication of patient assessment results 
with their primary care provider                                         
   
Follow-up after oupatient program    
Other (please specify): ________________    
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21. How many education sessions are provided to each patient in your program?     _____ (enter 
zero if none) 
 
22. How many minutes on average is each education session? ______ minutes (enter zero if 
none) 
 
23. In your program, do you assess the following risk factors? Please check one box per row.  
 Yes No 
Time spent being sedentary   
Tobacco use   
Harmful use of alcohol   
Blood pressure   
Body mass Index   
Waist circumference   
Hip circumference   
Body composition   
Total Cholesterol   
Cholesterol fractions (HDL-c, LDL-c)   
Triglycerides   
HbA1c for diabetic patients   
Blood glucose for non-diabetic patients   
Sleep apnea   
Depression / Anxiety   
Physical inactivity   
Poor diet   
Other (please specify:_______________)   
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24. Which types of personnel are part of your cardiovascular rehabilitation (CR) team? If they 
are part of your team, do they work in Cardiac Rehabilitation only, or do they have other 
department obligations? (Check one box in each row):  
 
a. Cardiologist                           Yes- only CR (   )   Yes- partial (   )  No   (   )   
b. Physiatrist (Physical medicine and rehabilitation) Yes- only CR (  )Yes- partial (  ) No (  )   
c. Sports Medicine Physician                       Yes- only CR (   )   Yes- partial (   )   No   (   ) 
d. Other Physician (specify:______________)Yes- only CR (   )   Yes- partial (   )   No   (   ) 
e. Physiotherapist                                             Yes- only CR (   )   Yes- partial (   )   No   (   ) 
f. Nurse               Yes- only CR (   )   Yes- partial (   )   No   (   ) 
g. Nurse practitioner                   Yes- only CR (   )   Yes- partial (   )   No   (   ) 
h. Psychiatrist                                     Yes- only CR (   )   Yes- partial (   )   No   (   ) 
i. Psychologist                                    Yes- only CR (   )   Yes- partial (   )   No   (   ) 
j. Social worker                    Yes- only CR (   )   Yes- partial (   )   No   (   ) 
k. Dietitian                                 Yes- only CR (   )   Yes- partial (   )   No   (   ) 
l. Kinesiologist              Yes- only CR (   )   Yes- partial (   )   No   (   )   
m. Pharmacist              Yes- only CR (   )   Yes- partial (   )   No   (   ) 
n. Exercise specialist             Yes- only CR (   )   Yes- partial (   )   No   (   ) 
o. Community Health worker            Yes- only CR (   )   Yes- partial (   )   No   (   ) 
p. Administrative assistant/ Secretary           Yes- only CR (   )   Yes- partial (   )   No   (   ) 
q. Other (specify): ___________________     Yes- only CR (   )   Yes- partial (   )   No   (   )  
 
25. Do all your clinical staff supervising patients during exercise sessions have 
cardiopulmonary resuscitation (CPR) training / certification? 
c Yes  
c No (skip to question 26) 
 
25b. If yes, are they required to renew their CPR training regularly? 
c Yes 
c No 
 
25c. If yes, is the CPR certification advanced or basic? (circle one per row) 
Physicians:          Advanced  Basic 
Nurses:           Advanced  Basic 
Other:                Advanced  Basic 
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26. Does your program have each of the following ítems, and if yes, is its’ use dedicated to your 
program or shared with another group (circle one option in each row)?  
 
Bicycle ergometer   Dedicated Shared  Not available 
Treadmill ergometer   Dedicated Shared  Not available 
Arm cycloergomenter   Dedicated Shared  Not available 
Doppler Echocardiography  Dedicated Shared  Not available 
Stress test (no O2)   Dedicated Shared  Not available 
Stress test with O2  Dedicated Shared  Not available 
Telemetry     Dedicated Shared  Not available 
Group education room   Dedicated Shared  Not available 
Gym space   Dedicated Shared  Not available 
Individual assessment/  Dedicated Shared  Not available 
Counselling room 
Patient change room  Dedicated Shared  Not available 
Administrative office  Dedicated Shared  Not available 
Electronic patient charts  Dedicated Shared  Not available 
Resistance training equipment Dedicated Shared  Not available 
Body composition analyzer  Dedicated Shared  Not available 
Staff meeting room  Dedicated Shared  Not available 
Staff office space   Dedicated Shared  Not available 
Other (specify):   Dedicated Shared  Not available 
 
27. Does your site offer a supervised Cardiac Rehabilitation program? 
  
c Yes   
c No (skip to section D) 
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SECTION C: CARDIAC REHABILITATION – Supervised Program 
 
28. Which of the following cardiac diagnoses or indications do you accept for your supervised 
program? (Check all that apply)  
c Post Myocardial Infarction / acute coronary syndrome   
c Stable coronary artery disease, without a recent event or procedure          
c Post percutaneous coronary intervention (PCI)   
c Post coronary artery bypass graft surgery (CABG)  
c Heart failure    
c Patients who have had valve surgery/repair or transcatheter aortic valve implantation 
(TAVI)  
c Heart transplant  
c Patients with ventricular assist devices 
c Arrhythmias (hemodynamically-stable) 
c Patients with implanted devices for rhythm control  (i.e., ICD / CRT, pacemaker)           
c Congenital heart disease 
c Cardiomyopathy 
c Rheumatic heart disease   
c Patients at high-risk of cardiovascular disease (primary prevention) 
c Non-cardiac chronic diseases 
c Other (specify): ____________________ 
 
29. Which of the following non-cardiac diagnoses or indications do you accept for your on-site 
program? (Check all that apply)   
c Stroke 
c Intermittent claudication / peripheral vascular disease 
c Cancer 
c Diabetes 
c Chronic lung disease 
c None 
c Other (specify): ____________________ 
 
30. Which of the following patient levels of cardiac risk do you accept for your supervised 
program?  (Check all that apply) 
c Low 
c Moderate 
c High 
c Not applicable because we do not risk stratify at our program 
 
31. Do patients have an individual consult with a physician during the program?  
  Yes, please specify # times in a full program: ______ 
  No 
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32. What is the standard duration of the on-site cardiac rehabilitation program that you provide 
to patients? 
__________ weeks  
 
33. On average, for how many sessions do patients come on-site each week?  
 
__________ sessions per week OR _____ sessions / day (residential 
programs) 
 
34. On average, how many patients are in each exercise session?  
 
 __________ patients / session  
 
35. On average, how long is each exercise session (including warm up, aerobic exercise, 
strength training and/ or cold down)?  
 
_______________ minutes / session 
 
36. What is the maximum number of patients that your program allows in the same exercise 
session? 
 
__________ patients / session 
 
37. What is the staff to patient ratio during supervised exercise at your program? _____:______ 
patients 
 
38. Which healthcare professionals are usually present during exercise sessions? (Check one 
box in each row)  
 
a. Cardiologist                             Yes (   )   No   (   )   
b. Physiatrist (Physical Medicine and Rehabilitation) Yes (   )   No   (   )   
c. Sports Medicine Physician               Yes (   )   No   (   )   
d. Other Physician (specify:___________________) Yes (   )   No   (   )   
e. Physiotherapist                             Yes (   )   No   (   )   
f. Nurse       Yes (   )   No   (   )   
g. Nurse practitioner           Yes (   )   No   (   )   
h. Psychiatrist                                 Yes (   )   No   (   )   
i. Psychologist                                Yes (   )   No   (   )   
j. Social worker            Yes (   )   No   (   )   
k. Dietitian                             Yes (   )   No   (   )   
l. Kinesiologist      Yes (   )   No   (   )   
m. Pharmacist      Yes (   )   No   (   )   
n. Exercise specialist     Yes (   )   No   (   )   
o. Community health worker    Yes (   )   No   (   )   
p. Other (specify): ______________________________________    
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39. Does the supervised program offer telemetry or another method of monitoring patients’ 
clinical status while exercising? (check all that apply) 
c Yes, telemetry 
c Yes, other method of monitoring; please specify: 
c Borg scale (perceived exertion) 
c Heart rate 
c Other: ______ 
c None 
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Appendix E  
ECO-PCR Informed Consent Form 
 
 
                             
 
 
CONSENT TO PARTICIPATE IN A RESEARCH STUDY 
 
 
Study Title: Ecologically Optimizing Exercise Maintenance in Men and 
Women Following Cardiac Rehabilitation: A Randomized 
Controlled Trial of Efficacy with Economics  
 
Principal Investigators: Dr. Robert Reid, PhD MBA (Ottawa) 
    Sherry L. Grace, PhD (Toronto) 
 
Sponsor   Heart and Stroke Foundation of Ontario 
 
 
Introduction 
 
You are being asked to take part in a research study. Please read this explanation about the study 
and its risks and benefits before you decide if you would like to take part. You should take as 
much time as you need to make your decision. You should ask the study doctor or study staff to 
explain anything that you do not understand and make sure that all of your questions have been 
answered before signing this consent form. Before you make your decision, feel free to talk 
about this study with anyone you wish. Participation in this study is voluntary. 
 
 
 
Background and Purpose 
 
Physical activity is an important contributor to fitness for patients with heart disease. Canadian 
guidelines recommend 30-60 minutes of moderate to vigorous physical activity most, preferably, 
all days of the week.  
 
Participation in an outpatient cardiac rehabilitation program is the usual first step toward 
developing an exercising lifestyle after a heart problem is diagnosed. About 70-85% of people 
report achieving recommended guidelines for physical activity during the time they are 
participating in cardiac rehab. Unfortunately, these levels of physical activity are often not 
maintained after participation in the program ends.  
 
 
111 
 
You have been asked to take part in this research study because you have graduated from a 
supervised cardiac rehabilitation program at the University Health Network (Toronto Western 
Hospital or Toronto Rehabilitation Institute). 
 
We have developed a new intervention to promote the continuation of exercise following cardiac 
rehab. It incorporates an exercise “facilitator” to transition patients from structured, supervised 
exercise to home walking or approved community-based exercise programs (also known as Heart 
Wise Exercise Programs).  
 
This research study will examine whether the facilitator intervention is related to more exercise 
maintenance over the year following cardiac rehab, which elements of the process affected your 
exercise, your clinical profile, and the cost of in the intervention, including whether patients are 
less likely to use the healthcare system. 
 
About 604 people from Ottawa and Toronto will be in the study. About 169 people will come 
from the University Health Network (Toronto Western Hospital and the Toronto Rehabilitation 
Institute cardiac rehab programs). 
 
Study Design  
 
This study is a one and a half year study that that will compare an intervention group (exercise 
facilitator) with a control group (usual care). Whether you assigned to the intervention or the 
control group will be decided randomly (by chance) like flipping a coin or rolling dice. The 
number of people getting study intervention will be 302 and the number of people in the control 
group will be 302. 
 
Study Procedures  
 
Questionnaires 
 
You will be asked to complete four (4) survey questionnaires: one at the beginning of the study, 
one at 26 weeks (6 months), one at 52 weeks (1 year) and one at 78 week (1.5 years). The 
questionnaires will ask you about your demographics (age, gender, education), lifestyle (exercise 
behaviours, cardiac risk factors, medications), as well as questions about your health and 
emotional well-being. Completion of the questionnaires will require approximately 45 minutes of 
your time. 
 
Intervention Group  
 
Participants in the intervention group will receive five small group counselling teleconferences, 
be invited to multiple community exercise program demonstrations, and three personal telephone 
calls from a trained exercise facilitator over a 50-week (almost 1 year) intervention period.  
• Small group teleconferences will take place in study weeks: 3, 13, 26, 39 and 50. These 
sessions are 20 minutes long. 
• Personal (individual phone calls) will take place in study weeks: 20, 34 and 45. These 
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sessions are 15 minutes long. 
• A random sub-sample of these calls would be audio-taped with your permission so we 
can audit the consistency of the session content the facilitator is providing. 
• The above activities will actively explore and review your exercise behaviours and 
barriers.  
Usual Care Group  
 
The usual care group will receive the usual exercise advice provided to patients exiting cardiac 
rehabilitation at the study centers. Patients in both programs are provided with an updated 
exercise prescription and a home-based walking program prior to program completion and 
exercise maintenance strategies are reviewed with program exercise staff. There is no further 
patient contact after program completion at either program.  
 
Follow up 
 
Participants in both groups will have their follow-up continue through to 78 weeks (1.5 years 
later). 
• Results from your exit assessments will be collected from your cardiac rehab charts. 
• Measures will be taken at 26 weeks (6 months), 52 weeks (1 year) and 78 weeks (1.5 
years) after randomization.  
• You will be asked to come on site for these assessments, and complete a survey 
measuring your thoughts and feelings about exercise. It will take approximately 45 
minutes to complete.  
• In order to measure your health, we would also like to test your blood pressure and 
measure your waist.  
• You will be asked wear an accelerometer device to measure your physical activity for 
9 days. You will be provided with a pre-paid addressed envelope to return the 
accelerometer. 
• All patients will be asked to do a physician-supervised, symptom-limited 
cardiopulmonary test at the 1-year assessment. Cardiac rehab graduates from the Toronto 
Rehabilitation Institute program are asked to do this as a standard part of the program, so 
if this information is available we would simply want to get the results.  
 
As part of the study, we will review your medical records to obtain information about your 
diagnosis and your medical history, including the nature of your cardiac problem, heart history 
and medications. We will also collect the information obtained as part of your rehab program, 
which includes test results, blood pressure and waist measurements, cholesterol levels, as well as 
your participation level and dates of attendance.  
 
Economic Measures 
 
Finally, we would also like permission to link your information gathered from this program with 
a provincial database to determine your health care use and health outcomes over time. This 
would not require any paperwork on your behalf.   
 
Reminders 
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While you are in this study you should continue with everything your family doctor or cardiac 
specialist has recommended. You will still receive your usual care from your family doctor and 
cardiac specialist. You do not have to stop or change anything. 
 
Potential Risks and Benefits  
 
It is very unlikely that participation in this research study will result in any side effects. The 
Cardiopulmonary stress test will require you to walk (starting at a low level with the speed and 
grade slowly increasing throughout the test) on a treadmill with electrodes on your chest in order 
to see how the heart works during exercise. It will help us measure your heart minimal and 
maximal exercise capacity. This test is based on your own efforts and you can stop at any time 
throughout the procedure. There will be a full medical staff supervising the stress test.  
 
 You will be revealing personal information about yourself; however this information will 
remain private.  
 
Benefits to Being in the Study 
 
You may receive direct benefit from being in this study by receiving further support to maintain 
exercise. Your participation will also help us improve the care of future cardiac patients 
following cardiac rehab participation.  
 
Voluntary Participation 
 
Your participation in this study is voluntary. You may decide not to be in this study, or to be in 
the study now, and then change your mind later. You may leave the study at any time without 
affecting your care. You may refuse to answer any question you do not want to answer.  
 
We will give you new information that is learned during the study that might affect your decision 
to stay in the study.   
 
 
Confidentiality 
 
If you agree to join this study, the study doctor and his/her study team will look at your personal 
health information and collect only the information they need for the study.  Personal health 
information is any information that could be used to identify you and includes your: 
• name 
• address 
• email address 
• OHIP number 
• new or existing medical records (including types, dates and results of medical tests or 
procedures) 
 
The information that is collected for the study will be kept in a locked and secure area by the 
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study doctor for 10 years.  Only the study team or the people or groups listed below will be 
allowed to look at your records.  Your participation in this study also may be recorded in your 
medical record at this hospital.   
 
 
 
The following people may come to the hospital to look at the study records and at your personal 
health information to check that the information collected for the study is correct and to make 
sure the study followed proper laws and guidelines: 
• Representatives of the study organizing committee.   
• University Health Network Research Ethics Board.   
 
All information collected during this study, including your personal health information, will be 
kept confidential and will not be shared with anyone outside the study unless required by law.  
Any information about you that is sent out of the hospital will have a code and will not show 
your name or address, or any information that directly identifies you.  You will not be named in 
any reports, publications, or presentations that may come from this study.   
 
If you decide to leave the study, the information about you that was collected before you left the 
study will still be used.  No new information will be collected without your permission.  
 
In Case You Are Harmed in the Study 
 
If you become ill, injured or harmed as a result of taking part in this study, you will receive care. 
The reasonable costs of such care will be covered for any injury, illness or harm that is directly a 
result of being in this study. In no way does signing this consent form waive your legal rights nor 
does it relieve the investigators, sponsors or involved institutions from their legal and 
professional responsibilities. You do not give up any of your legal rights by signing this consent 
form.  
 
Expenses Associated with Participating in the Study  
 
You will not have to pay for any of the procedures (i.e. stress test) involved with this study. You 
will be reimbursed for your parking costs for your 4 on-site visits to complete study assessments 
(initial, 26, 52 and 78 weeks). You will not be paid for participation in this study. 
 
 
Questions About the Study 
 
If you have any questions, concerns or would like to speak to the study team for any reason, 
please call: Sherry Grace, PhD at 416-603-5800 x. 3495# or the Study Coordinator at 416-736-
2100 x20575.  
 
If you have any questions about your rights as a research participant or have concerns about this 
study, call the Chair of the University Health Network Research Ethics Board (REB) at 416-581-
7849 or please call the Toronto Rehab Research Ethics Board Office at (416) 597-3422 
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x 3081.The REB is a group of people who oversee the ethical conduct of research studies. These 
people are not part of the study team. Everything that you discuss will be kept confidential.  
 
 
Consent  
 
This study has been explained to me and any questions I had have been answered. I know that I 
may leave the study at any time. I agree to take part in this study.  
 
 
           
Print Study Participant’s Name  Signature   Date  
 
(You will be given a signed copy of this consent form) 
 
My signature means that I have explained the study to the participant named above. I have 
answered all questions.  
 
 
           
Print Name of Person    Signature   Date  
Obtaining Consent 
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Appendix F  
ECO-PCR Intervention 
 
